16,279 results on '"Chronic liver disease"'
Search Results
2. The prevalence of osteoporosis and its association with serum testosterone and serum vitamin D in the elderly male population: A cross-sectional study
- Author
-
Vivek Vasdev, Vivek Aggarwal, Manish Manrai, Premdeep Chauhan, and J. Muthukrishnan
- Subjects
0301 basic medicine ,COPD ,medicine.medical_specialty ,Cross-sectional study ,business.industry ,030106 microbiology ,Osteoporosis ,Alcohol dependence ,General Medicine ,medicine.disease ,Chronic liver disease ,Osteopenia ,03 medical and health sciences ,0302 clinical medicine ,Internal medicine ,medicine ,Outpatient clinic ,030212 general & internal medicine ,business ,Kidney disease - Abstract
Background Male osteoporosis is under-diagnosed and poorly studied. With the ageing population, osteoporotic fracture in men is an emerging health problem. The aim of this study was to study the prevalence of osteoporosis and its association with serum testosterone and serum vitamin D in elderly men (>60 years old) attending the outpatient department (OPD). Methods An observational cross-sectional study was performed in elderly men (>60 years old) attending OPD of a tertiary care hospital of Western Maharashtra between April 2017 and June 2019. Patients with rheumatological disorders, history of vertebral/femoral fractures, chronic kidney disease, chronic liver disease, thyroid disorders and alcohol dependence were excluded. Data were analysed using the chi-square test and descriptive statistics. Results In total, 408 male patients were included. The mean age was 68.33 years. Osteoporosis was seen in 39.5% of patients (161/408) with a T score of ≤2.5. Osteopenia was noted in 48.3% of patients (197/408). T and Z scores had significant correlation (p = Conclusion Osteoporosis was noted in 39.5% of the elderly men. In addition, decreased testosterone, COPD and BPH were significantly associated with male osteoporosis. It is important to screen elderly men to diagnose osteoporosis early and prevent osteoporotic fractures.
- Published
- 2023
3. First presentation of portal hypertension complicated by hepatopulmonary syndrome
- Author
-
Ceyhun Aksel Oztumer, Mohamed Saleh, Nahima Miah, and Aidan Ryan
- Subjects
Adult ,Liver Cirrhosis ,Male ,medicine.medical_specialty ,Cirrhosis ,medicine.diagnostic_test ,business.industry ,medicine.medical_treatment ,General Medicine ,Liver transplantation ,medicine.disease ,Chronic liver disease ,Pulmonary hypertension ,Liver Transplantation ,Respiratory failure ,Internal medicine ,Liver biopsy ,Hypertension, Portal ,Cardiology ,Medicine ,Portal hypertension ,Humans ,business ,Hepatopulmonary syndrome ,Hepatopulmonary Syndrome - Abstract
Hepatopulmonary syndrome (HPS) is a serious complication of chronic liver disease, characterised by portal hypertension and arterial hypoxaemia due to intrapulmonary vascular dilatation. We report an unusual case in which a 27-year-old man had a first presentation of portal hypertension and cirrhosis complicated by HPS. This patient presented with progressive dyspnoea on exertion and deterioration in mobility, with a type 1 respiratory failure and increased oxygen demand. A bubble echocardiogram showed a possible right-to-left shunt, CT aortogram displayed evidence of portal hypertension and cirrhosis, and liver biopsy findings were consistent with alpha-1 antitrypsin deficiency. The patient’s increased oxygen demand was subsequently treated with continuous positive airway pressure before he was discharged with 8 L home oxygen. With no current established medical therapy for HPS, the patient was assessed for liver transplantation and a decision was made in favour of this.
- Published
- 2023
4. Circulating PCSK7 Level is Independently Associated with Obesity, Triglycerides Level and Fatty Liver Index in a General Population without Medication
- Author
-
Yu Kataoka, Ryo Nishikawa, Marenao Tanaka, Masato Furuhashi, Masayuki Koyama, Hirofumi Ohnishi, Shigeyuki Saitoh, Kazuaki Shimamoto, Akiko Sakai, and Yukimura Higashiura
- Subjects
Male ,medicine.medical_specialty ,Iron ,Population ,Chronic liver disease ,Cohort Studies ,Non-alcoholic Fatty Liver Disease ,Internal medicine ,Internal Medicine ,Humans ,Medicine ,Obesity ,Subtilisins ,education ,Blood urea nitrogen ,Triglycerides ,education.field_of_study ,business.industry ,PCSK9 ,Biochemistry (medical) ,Fatty liver ,gamma-Glutamyltransferase ,medicine.disease ,Endocrinology ,Female ,Proprotein Convertase 9 ,Cardiology and Cardiovascular Medicine ,business ,Body mass index ,Dyslipidemia - Abstract
Aim Dyslipidemia and altered iron metabolism are typical features of non-alcoholic fatty liver disease (NAFLD). Proprotein convertase subtilisin/kexin type 7 (PCSK7), a transmembrane-anchored endonuclease, is associated with triglycerides level and processing of transferrin receptor 1. However, the significance of circulating PCSK7 has not been fully addressed, though prosegment PCSK7 is secreted from cells. We investigated the associations of plasma PCSK7 level with several parameters. Methods Plasma PCSK7 concentration was measured in 282 subjects (male/female: 126/156) without medication of the Tanno-Sobetsu Study, a population-based cohort study. Results There was no significant sex difference in PCSK7 level. Current smoking habit, but not alcohol drinking habit, was associated with increased PCSK7 level. PCSK7 concentration was negatively correlated with age and blood urea nitrogen and was positively correlated with body mass index (BMI) and levels of γ-glutamyl transpeptidase (γGTP), triglycerides and fatty liver index (FLI), which is calculated by BMI, waist circumference and levels of γGTP and triglycerides, as a noninvasive and simple predictor of NAFLD. There were no significant correlations of PCSK7 level with levels of iron and plasma PCSK9, a secreted PCSK family member and a regulator of low-density lipoprotein cholesterol level. Multivariable regression analyses after adjustment of age, sex and current smoking habit showed that PCSK7 concentration was independently associated with BMI (β=0.130, P=0.035), triglycerides (β=0.141, P=0.027) or FLI (β=0.139, P=0.030). Conclusions Plasma PCSK7 concentration is independently associated with chronic liver disease including obesity and elevated triglycerides level in a general population of individuals who had not regularly taken any medications.
- Published
- 2022
5. Sarcopenia in chronic advanced liver diseases: A sex-oriented analysis of the literature
- Author
-
Federica Invernizzi, Lucia Lapenna, Valentina Cossiga, Ilaria Lenci, C. Becchetti, Filomena Morisco, Alberto Zanetto, Patrizia Burra, Luisa Pasulo, Maria Guarino, Bruna Lavezzo, and Manuela Merli
- Subjects
Liver Cirrhosis ,Male ,Sarcopenia ,medicine.medical_specialty ,Carcinoma, Hepatocellular ,medicine.medical_treatment ,Liver transplantation ,Chronic liver disease ,Muscle mass ,Liver disease ,Quality of life ,Internal medicine ,gender ,medicine ,sex ,Humans ,Retrospective Studies ,Hepatology ,business.industry ,Incidence (epidemiology) ,Liver Neoplasms ,Gastroenterology ,musculoskeletal system ,medicine.disease ,body regions ,Hepatocellular carcinoma ,Quality of Life ,Female ,610 Medizin und Gesundheit ,liver disease ,business ,human activities ,sarcopenia - Abstract
Sarcopenia, defined as progressive and generalized loss of muscle mass and strength, is common in chronic liver disease. It significantly impacts the quality of life and increases the risk of liver-related complications and mortality in cirrhotic patients. Moreover, recent studies showed a negative impact of sarcopenia on patients awaiting liver transplantation (LT), on post-LT outcomes, and on response to hepatocellular carcinoma therapies. Data about the influence of sex on the incidence, prevalence, diagnosis and treatment of sarcopenia in chronic liver diseases are poor and conflicting. The aims of this review of the literature are to define sex differences in sarcopenic cirrhotic patients and to highlight the necessity of a sex stratified analysis in future studies. This analysis of the literature showed that most of the studies are retrospective, with a higher prevalence of sarcopenia in males, probably due to anatomical differences between the sexes. Moreover, diagnostic criteria for sarcopenia are different between studies, as there is not a defined cut-off and, as a consequence, no comparable results. In conclusion, sex seems to have an impact on sarcopenia, and future studies must accurately investigate its role in identifying and treating high-risk patients, reducing the negative impact of sarcopenia on the survival and quality of life of cirrhotic patients.
- Published
- 2022
6. SARS-CoV-2 infection in patients with autoimmune hepatitis
- Author
-
Thomas Marjot, Gustav Buescher, Marcial Sebode, Eleanor Barnes, A. Sidney Barritt, Matthew J. Armstrong, Luke Baldelli, James Kennedy, Carolyn Mercer, Ann-Kathrin Ozga, Christian Casar, Christoph Schramm, Andrew M. Moon, Gwilym J. Webb, and Ansgar W. Lohse
- Subjects
0301 basic medicine ,medicine.medical_specialty ,Cirrhosis ,medicine.medical_treatment ,Autoimmune hepatitis ,Antibodies, Viral ,Chronic liver disease ,Gastroenterology ,Article ,Immunocompromised Host ,03 medical and health sciences ,Liver disease ,0302 clinical medicine ,immune system diseases ,Internal medicine ,medicine ,Humans ,immunosuppression ,autoimmune hepatitis ,Hepatology ,SARS-CoV-2 ,business.industry ,COVID-19 ,Immunosuppression ,medicine.disease ,digestive system diseases ,Hepatitis, Autoimmune ,030104 developmental biology ,Immunosuppressive drug ,Cohort ,Etiology ,030211 gastroenterology & hepatology ,business - Abstract
Background Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease 2019 (COVID-19) continues to have a devastating impact across the globe. However, little is known about the disease course in patients with autoimmune hepatitis (AIH). Methods Data for patients with AIH and SARS-CoV-2 infection were combined from three international reporting registries and outcomes were compared to those with chronic liver disease of other aetiology (non-AIH CLD) and to patients without liver disease (non-CLD). Results Between 25th March and 24th October 2020, data were collected for 932 patients with CLD and SARS-CoV-2 infection including 70 with autoimmune hepatitis (AIH). Fifty-eight (83%) of AIH patients were taking one or more immunosuppressive drug. There were no differences in rates of major outcomes between AIH and non-AIH CLD including hospitalization (76% vs 85%; p= 0.06), ICU admission (29% vs. 23%; p=0.240), and death (23% vs. 20%; p=0.643). Factors associated with death within the AIH cohort included age (OR 2.16/10 years; 1.07–3.81), Child-Turcotte-Pugh (CTP) class B (OR 42.48; 4.40–409.53), and CTP-C cirrhosis (OR 69.30; 2.83–1694.50), but not use of immunosuppression. Propensity score matched (PSM) analysis comparing AIH with non-AIH CLD demonstrated no increased risk adverse outcomes including death (+3.2%; -9.2%–15.7%). PSM analysis of AIH versus non-CLD patients (n=769) demonstrated increased risk of hospitalization with AIH (+18.4%; 5.6–31.2%), but equivalent risk of all other outcomes including death (+3.2%; -9.1%–15.6%). Conclusion AIH patients were not at increased risk of adverse outcomes despite immunosuppressive treatment compared to other causes of CLD and to matched cases without liver disease., Graphical abstract, Highlights • This is the largest cohort of patients with autoimmune hepatitis and laboratory proven SARS-COV-2 infection reported to date. • There were no differences in rates of major adverse COVID-19 outcomes including hospitalization, intensive care unit (ICU) admission, and death between AIH patients and those with other aetiologies of liver disease. • When compared to patients without liver disease in propensity score matched analysis, patients with AIH had higher rates of hospitalization but no increased risk of ICU admission or death despite potential reporting of AIH cases with more severe baseline liver disease. • Independent risk factors for death in AIH patients were age and baseline liver disease severity, but not the use of immunosuppression., Lay summary: Little is known about the outcomes of COVID-19 in patients with autoimmune hepatitis (AIH), a rare chronic inflammatory liver disease. This study combines data from three large registries to describe the course of COVID-19 in this patient group. We show that AIH patients do not appear to have an increased risk of death from COVID-19 compared to patients with other forms of liver disease and compared to patients without liver disease, despite the use of medications which suppress the immune system.
- Published
- 2023
7. Application of Noninvasive Tools to Decide the Need for Beta-Blockers for Variceal Bleeding Prophylaxis in Compensated Advanced Liver Disease: A Decision Curve Analysis
- Author
-
Sushrut Singh, Rakesh Kumar Jagdish, Ankur Kumar Jindal, Sanchit Sharma, Samagra Agarwal, Anoop Saraya, Shiv Kumar Sarin, and Deepak Gunjan
- Subjects
medicine.medical_specialty ,Hepatology ,medicine.diagnostic_test ,business.industry ,Hepatitis C ,Hepatitis B ,Chronic liver disease ,medicine.disease ,Gastroenterology ,Endoscopy ,Liver disease ,Internal medicine ,Nonalcoholic fatty liver disease ,medicine ,Number needed to treat ,Original Article ,business ,Varices - Abstract
BACKGROUND AND AIMS: Noninvasive tools (NITs) reliably categorise patients with compensated advanced chronic liver disease (cACLD) into high-risk and low-risk group for harbouring varices needing treatment. Here, we assess the ability of these NITs to predict the need for nonselective beta-blockers at baseline based on risk of variceal bleeding (VB) on follow-up. METHODS: This was a retrospective multicentre analysis of patients with cACLD categorised at baseline into different risk groups by NITs (Baveno-VI, expanded Baveno-VI, platelet-albumin, platelet-model for end-stage liver disease (MELD) and anticipate study platelet criteria) and by endoscopy (high risk vs low risk/no varices). VB event rates on follow-up were estimated in different risk strata. Decision curve analysis (DCA) was used to estimate the benefit of administering nonselective beta-blockers (NSBB) using NITs over endoscopic classification at different threshold probabilities of VB event rates and estimating the number needed to treat (NNT) to identify one additional bleeder over endoscopy. RESULTS: A total of 1284 patients (mean age: 44.7 ± 13.5 years, 72.4% males) of hepatitis B (29.2%), nonalcoholic fatty liver disease (24.9%), hepatitis C (20.1%), and alcohol (17.5%)-related cACLD were included with 323 (25.2%) having high-risk varices. Ninety-eight (7.6%) patients developed VB over a median follow-up of 20 (9–35) months. The 1-year and 3-year rate of VB with all NITs was 5.7–7.4% and 13.2–16.4% among high-risk and 0–2.3% and 0–5% among low-risk subgroups, respectively (P
- Published
- 2022
8. The Outcome in Cirrhosis after Hospital Discharge is Not Worsened with COVID-19 Infection: A Propensity Score-matched Analysis
- Author
-
Amit Goel, Manas Vaishnav, Anshuman Elhence, Shalimar, Sabreena Sheikh, Abhinav Anand, Vishwajeet Singh, Piysuh Pathak, Souvik Maitra, and Sagnik Biswas
- Subjects
medicine.medical_specialty ,Cirrhosis ,Hepatology ,Bilirubin ,business.industry ,medicine.disease ,Chronic liver disease ,Gastroenterology ,Liver disease ,chemistry.chemical_compound ,chemistry ,Internal medicine ,Ascites ,Propensity score matching ,medicine ,Etiology ,medicine.symptom ,business ,Hepatic encephalopathy - Abstract
Background Patients with cirrhosis and coronavirus disease-2019 (COVID-19) have high in-hospital mortality. The information on outcome of cirrhosis patients in post-hospitalization period are limited. Aims We aimed to study the outcome of cirrhosis patients with COVID-19 after hospital discharge. Methods The records of the cirrhosis patients discharged after COVID-19 were reviewed. Their data were compared with a similar number of cirrhosis patients without COVID-19 after propensity score matching for age, sex, etiology of cirrhosis, and model for end-stage liver disease (MELD) score. Results Cirrhosis patients with (n=92) or without (n=92) COVID-19 were included in 1:1 ratio. The mortality among COVID-19 (22; 23.9%) and non-COVID-19 (19; 20.7%) were comparable (HR 1.224; 95% CI 0.663-2.263, P=0.520), over a similar duration of follow-up [186 (86-271) vs 183 (103-274)]. Among COVID-19 patients, 45; 48.9% developed a new acute decompensation-increased ascites (40; 43.5%), hepatic encephalopathy (20; 21.7%), or variceal bleeding (8; 8.7%) whereas 25 (27.2%) patients needed re-hospitalization. A proportion of participants continued to have either fatigue/weakness (24/80; 30.0%), sleep disturbances (11/80; 13.7%), or joint pains (16/80; 20.0%). The most common causes of death in patients of both groups were end-stage liver disease: 16 (72.7%) vs 9 (47.4%), followed by multiorgan dysfunction: 4 (18.2%) vs 6 (31.6%), GI bleeding: 2 (9.1%) vs. 4 (21.0%), P=0.484. A lower albumin level, higher international normalized ratio, bilirubin, Child-Turcotte-Pugh, and MELD scores at discharge predicted mortality in the COVID-19 group. Conclusion Short-term outcomes of patients with cirrhosis who survive the initial insult of COVID-19 are not different from patients without COVID-19, and survival is determined by the severity of liver disease at discharge.
- Published
- 2022
9. Leaky gut-derived tumor necrosis factor-α causes sarcopenia in patients with liver cirrhosis
- Author
-
Takuji Torimura and Takumi Kawaguchi
- Subjects
Liver Cirrhosis ,Sarcopenia ,medicine.medical_specialty ,Cirrhosis ,Hepatology ,Tumor Necrosis Factor-alpha ,business.industry ,medicine.disease ,Chronic liver disease ,Gastroenterology ,Muscle atrophy ,Internal medicine ,Gut permeability ,Humans ,Medicine ,Tumor necrosis factor alpha ,In patient ,medicine.symptom ,business ,Molecular Biology - Published
- 2022
10. Association between serum tumor necrosis factor-α and sarcopenia in liver cirrhosis
- Author
-
Hee Chul Nam, Do Seon Song, Da In Kim, U Im Chang, Jin Mo Yang, and Ji Won Han
- Subjects
Liver Cirrhosis ,Sarcopenia ,medicine.medical_specialty ,Cirrhosis ,H&E stain ,Myostatin ,Chronic liver disease ,Rifaximin ,Rats, Sprague-Dawley ,chemistry.chemical_compound ,Internal medicine ,medicine ,Animals ,Humans ,Molecular Biology ,Hepatology ,biology ,Tumor Necrosis Factor-alpha ,business.industry ,Skeletal muscle ,musculoskeletal system ,medicine.disease ,Rats ,Endocrinology ,medicine.anatomical_structure ,Liver ,chemistry ,biology.protein ,Tumor necrosis factor alpha ,Thioacetamide ,business - Abstract
Background/Aims: Sarcopenia is an independent prognostic factor of liver cirrhosis (LC). However, the association between LC-related systemic inflammation and sarcopenia is unclear.Methods: Sprague-Dawley rats were treated with thioacetamide (TAA) or saline as a control. Rifaximin was administered to TAA-induced LC rats. Enzyme-linked immunosorbent assay was performed to measure inflammatory mediators in rat serum. RT-PCR was performed to measure the molecular expression in tissues. Hematoxylin and eosin (H&E) staining and immunohistochemistry were performed to investigate tissue pathology. Serum tumor necrosis factor-α levels, liver stiffness (LS), and the L3 skeletal muscle index (L3SMI) were measured in 60 patients with chronic liver disease.Results: LC and sarcopenia were successfully induced by TAA. Serum TNF-α levels were increased in LC rats and correlated with myostatin expression, muscle weight, and myofiber diameter. The expression of intestinal occludin and zona occludens-1 was reduced in LC rats and associated with serum TNF-α levels and sarcopenia. In patients with LS ≥7 kPa or sarcopenia, serum TNF-α levels were significantly increased, which was also confirmed when we raised the LS cutoff to 10 kPa. The L3SMI was inversely correlated with serum TNF-α levels in patients with LS ≥7 kPa. TNF-α was reduced by rifaximin, which might have resulted in reduced expression of muscular MuRF1 and myostatin and improvements in myofiber diameters within muscle tissues.Conclusions: These results suggest that serum TNF-α is associated with LC-related sarcopenia. Rifaximin might be effective in reducing serum TNF-α levels and improving sarcopenia in LC, but these results need to be validated in future studies.
- Published
- 2022
11. Reply to: non-invasive tests and advanced chronic liver disease in NAFLD: two steps forward and one step back?
- Author
-
Michael Pavlides, Ferenc E. Mózes, and Stephen A. Harrison
- Subjects
Liver Cirrhosis ,medicine.medical_specialty ,Cirrhosis ,Carcinoma, Hepatocellular ,medicine.diagnostic_test ,business.industry ,Non invasive ,Fatty liver ,Liver Neoplasms ,Gastroenterology ,Fibrosis stage ,medicine.disease ,Chronic liver disease ,Advanced fibrosis ,Liver ,Non-alcoholic Fatty Liver Disease ,Liver biopsy ,Internal medicine ,Hepatocellular carcinoma ,medicine ,Humans ,business - Abstract
We appreciate the interest in our study by Majumdar and Tsochatzis1 and welcome the opportunity to provide some clarifications. The literature to date has examined non-invasive test (NIT) algorithms to rule-in and rule-out advanced fibrosis (AF). The main use of such algorithms is to identify those at low risk of AF who can be managed in primary care. We propose an algorithm2 where the rule-out cut-offs remain optimised for AF, whereas the rule-in cut-offs are optimised for cirrhosis. The false-negative (FN) rate of 10% in our proposed algorithm refers to the FN rate for AF and not cirrhosis as Majumdar and Tsochatzis state in their letter.1 Only 18/570 (3%) of patients with cirrhosis are missed using our proposed algorithm (table 1). View this table: Table 1 Number of patients with fibrosis stage F0–2, F3 and F4 according to LSM cut-offs recommended by the Baveno 6 consensus (10 and 15 kPa) and our previous paper (8 and 20, and 8 and 28 kPa) We also argue2 that patients with NITs above the rule-in cut-off for AF should undergo liver biopsy to identify those with cirrhosis who should undergo …
- Published
- 2023
12. A Comparison of Different Frailty Scores and Impact of Frailty on Outcome in Patients With Cirrhosis
- Author
-
Akash Roy, Arka De, Madhumita Premkumar, Akash Bansal, Surender Singh, Virendra Singh, Puneeta Tandon, Nipun Verma, Ujjwal Gorsi, Sunil Taneja, Radha K. Dhiman, and Ajay Duseja
- Subjects
medicine.medical_specialty ,Alcoholic liver disease ,Cirrhosis ,Hepatology ,business.industry ,Mortality rate ,Gold standard ,Hepatitis C ,medicine.disease ,Chronic liver disease ,Internal medicine ,Cohort ,Medicine ,Original Article ,business ,human activities ,Cohort study - Abstract
Background & aims There is no “gold standard” tool for the assessment of frailty in cirrhosis. This study compares Liver Frailty Index (LFI), Short Physical Performance Battery (SPPB), Fried Frailty Criteria (FFC), and Clinical Frailty Scale (CFS) for frailty assessment and ascertains its impact on predicting mortality and hospitalizations in a cohort of outpatients with cirrhosis. Methods 116 patients were enrolled in this prospective observational cohort study. Frailty assessment was done using LFI, SPPB, FFC, and CFS. All patients were followed up for 6 months. The primary outcome was the first of either all-cause unplanned hospitalization or all-cause mortality occurring within 6 months of the study period. Results 100 (86.2%) males and 16 (13.8%) females with a mean age of 50.2 (48.4–51.9, 95% CI) years were included. The most common cause of cirrhosis was alcoholic liver disease (47.4%) followed by hepatitis C (12.9%) and Nonalcoholic steatohepatitis (NASH) (10.3%). There was no significant difference in prevalence of frailty based on LFI (43.1%), FFC (36.2%), CFS (44%), and SPPB (47.4%) (P > 0.05). Frail patients had worse outcomes compared to the Not frail group. At 6 months, the mortality rate in Frail patients was 42% versus 1.5% for the Not frail; hospitalization in Frail patients occurred in 92% versus 6% in the Not frail. On multivariable analysis, independent predictors of mortality were Frailty [OR 14 (1.4–54.2)], alcohol-related cirrhosis [OR 4.2 (1.1–16.3)], Child-Turcotte-Pugh (CTP) [OR 2.1 (1.4–2.9)] and Chronic liver disease questionnaire (CLDQ) [OR 0.1 (0.1–0.4)] scores. Conclusions LFI, SPPB, FFC, and CFS are comparable in frailty assessment in patients with cirrhosis. Importantly, comparability of the commonly used scores for frailty assessment and prediction of hospitalization and mortality allows flexibility for clinical application.
- Published
- 2022
13. Gut-derived systemic inflammation as a driver of depression in chronic liver disease
- Author
-
Carmine M. Pariante, Thomas H. Tranah, Debbie L. Shawcross, and Victoria T. Kronsten
- Subjects
Inflammation ,education.field_of_study ,Cirrhosis ,Hepatology ,Depression ,business.industry ,Liver Diseases ,medicine.medical_treatment ,Population ,medicine.disease ,Systemic inflammation ,Chronic liver disease ,Gastrointestinal Microbiome ,Cytokine ,Immunology ,Disease Progression ,medicine ,Humans ,medicine.symptom ,business ,education ,Irritable bowel syndrome ,Depression (differential diagnoses) ,Neuroinflammation - Abstract
Depression and chronic liver disease (CLD) are important causes of disability, morbidity and mortality worldwide and their prevalence continues to rise. The rate of depression in CLD is high compared to that of the general population and is comparable to the increased rates observed in other medical comorbidities and chronic inflammatory conditions. Notably, a comorbid diagnosis of depression has a detrimental effect on outcomes in cirrhosis. Systemic inflammation is pivotal in cirrhosis-associated immune dysfunction - a phenomenon present in advanced CLD (cirrhosis) and implicated in the development of complications, organ failure, disease progression, increased infection rates and poor outcome. The presence of systemic inflammation is also well-documented in a cohort of patients with depression; peripheral cytokine signals can result in neuroinflammation, behavioural change and depressive symptoms via neural mechanisms, cerebral endothelial cell and circumventricular organ signalling, and peripheral immune cell-to-brain signalling. Gut dysbiosis has been observed in both patients with cirrhosis and depression. It leads to intestinal barrier dysfunction resulting in increased bacterial translocation, in turn activating circulating immune cells, leading to cytokine production and systemic inflammation. A perturbed gut-liver-brain axis may therefore explain the high rates of depression in patients with cirrhosis. The underlying mechanisms explaining the critical relationship between depression and cirrhosis remain to be fully elucidated. Several other psychosocial and biological factors are likely to be involved, and therefore the cause is probably multifactorial. However, the role of the dysfunctional gut-liver-brain axis as a driver of gut-derived systemic inflammation requires further exploration and consideration as a target for the treatment of depression in patients with cirrhosis.
- Published
- 2022
14. Prevalence and Predictors of Nonalcoholic Fatty Liver Disease in Family Members of Patients With Nonalcoholic Fatty Liver Disease
- Author
-
Anshuman Elhence, Ramesh Kumar, Abhinav Anand, Deepak Gunjan, Sagnik Biswas, Amit Anurag Singh, Shivanand Gamanagatti, Baibaswata Nayak, Shalimar, and Manas Vaishnav
- Subjects
medicine.medical_specialty ,Hepatology ,Receiver operating characteristic ,business.industry ,Fatty liver ,nutritional and metabolic diseases ,Disease ,medicine.disease ,Chronic liver disease ,digestive system ,digestive system diseases ,Confidence interval ,Internal medicine ,Nonalcoholic fatty liver disease ,medicine ,Original Article ,Observational study ,business ,Body mass index - Abstract
BACKGROUND AND AIMS: Nonalcoholic fatty liver disease (NAFLD) is the commonest cause of chronic liver disease worldwide. Despite the high prevalence, no screening recommendations yet exist. We designed a prospective observational study to estimate the prevalence of NAFLD in the family of patients with NAFLD and develop a predictive model for identifying it. METHODOLOGY: The prevalence of NAFLD in patients’ family members was estimated using ultrasonography, and univariate and multivariate odds were calculated for its predictors. A model was created using the significant parameters on multivariate odds, and its performance was tested using the area under the receiver operating characteristic (AUROC). RESULTS: Among 447 family members of 191 patients with NAFLD, the prevalence of NAFLD was 55.9%. Family members with NAFLD were younger and had lower serum levels of aspartate aminotransferase, alanine aminotransferase (ALT), triglycerides. The liver stiffness measurement and controlled attenuation parameter values were also lesser in family members compared to the index cases. Age, body mass index (BMI), and ALT were independent predictors of NAFLD in the family members. A model combining age and BMI had an AUROC of 0.838 [95% confidence interval (CI) 0.800–0.876, P < 0.001]. Age ≥30 years and BMI ≥25 kg/m(2) had an odds ratio of 33.5 (95% CI 17.0–66.0, P < 0.001) for prediction of NAFLD, in comparison to BMI
- Published
- 2022
15. Hepatogenous Diabetes - A Report from Central India
- Author
-
Praveen Vasepalli, Mohd Talha Noor, and Bhagwan S. Thakur
- Subjects
medicine.medical_specialty ,Cirrhosis ,Hepatology ,business.industry ,medicine.disease ,Chronic liver disease ,Gastroenterology ,Impaired glucose tolerance ,chemistry.chemical_compound ,Liver disease ,Insulin resistance ,chemistry ,Internal medicine ,Diabetes mellitus ,medicine ,Original Article ,Glycated hemoglobin ,Liver function ,business - Abstract
BACKGROUND/OBJECTIVES: Cirrhosis of liver is associated with loss of liver function, portal hypertension, and pancreatic β-cell dysfunction leading to hepatogenous diabetes (HD). Often HD is an underestimated and understudied problem, particularly in the Indian subcontinent, where the prevalence of both Chronic liver disease (CLD) and diabetes is high. Hence this study was planned to highlight the prevalence of HD and its association with the severity of cirrhosis. METHODS: A total of 121 cirrhotic patients without a history of diabetes were included in this prospective cross-sectional study. Seventy five g oral glucose tolerance test (OGTT) was done in all patients. Fasting serum insulin levels were done to calculate insulin resistance (IR) using homeostatic model assessment-insulin resistance (HOMA-IR). Upper gastrointestinal endoscopy was done to detect varices. Patients were divided into HD group and non-HD group for comparison of results. RESULTS: HD was seen in 52 (42.98%) patients; among them, 63.4% did not show evidence of HD by fasting plasma glucose (FPG) levels. Impaired glucose tolerance (IGT) was seen in 58 (47.93%) patients. Compared with the non-HD group, the HD group had significantly higher model for end-stage liver disease (MELD) score (P = 0.038), HOMA-IR (P 15), CTP score (>10), higher bilirubin levels, large varices, bleeding varices, and HCC. FPG levels and glycated hemoglobin (HbA1c) cannot be relied upon, and OGTT aids in the unmasking of HD in these patients.
- Published
- 2022
16. Treatment and outcomes of hepatocellular carcinoma in patients with Sickle cell disease: a population-based study in the U.S
- Author
-
Sean P. Martin, Angelina Lim, Jeffrey Kahn, Cameron Goldbeck, Arianna Barbetta, Juliet Emamaullee, and M. Raashid Sheikh
- Subjects
Oncology ,congenital, hereditary, and neonatal diseases and abnormalities ,medicine.medical_specialty ,Carcinoma, Hepatocellular ,Cirrhosis ,Cell ,Population ,Anemia, Sickle Cell ,Disease ,Medicare ,Chronic liver disease ,Article ,hemic and lymphatic diseases ,Internal medicine ,medicine ,Humans ,cardiovascular diseases ,Propensity Score ,education ,Aged ,Retrospective Studies ,education.field_of_study ,Hepatology ,business.industry ,Liver Neoplasms ,Gastroenterology ,medicine.disease ,United States ,digestive system diseases ,Treatment Outcome ,medicine.anatomical_structure ,Hemoglobinopathy ,Hepatocellular carcinoma ,Propensity score matching ,business - Abstract
BACKGROUND: Sickle cell disease (SCD) is a rare hemoglobinopathy which can result in chronic liver disease and cirrhosis. Patients with SCD have an increased risk of hematologic malignancy, but the prevalence of hepatocellular carcinoma (HCC) in this population is unknown. Herein, the association of SCD with HCC was examined using registry data. METHODS: The SEER-Medicare database was queried to identify patients diagnosed with HCC between 2000 and 2015, and further stratified by SCD status. Propensity matching was performed to examine cancer-related survival and treatment outcomes. RESULTS: Overall 56,934 patients with HCC were identified, including 81 patients with SCD. Patients with SCD more frequently had cirrhosis [48.1% (39/81) vs 23.5% (13,377/56,853), p
- Published
- 2022
17. Endoscopic Bariatric Interventions in Patients with Chronic Liver Disease
- Author
-
Marco Bustamante-Bernal, Marc J. Zuckerman, and Luis O. Chavez
- Subjects
medicine.medical_specialty ,Gastroplasty ,medicine.medical_treatment ,Population ,Psychological intervention ,Bariatric Surgery ,Disease ,Liver transplantation ,Chronic liver disease ,Gastroenterology ,Bariatrics ,Non-alcoholic Fatty Liver Disease ,Internal medicine ,Nonalcoholic fatty liver disease ,Humans ,Medicine ,Obesity ,education ,education.field_of_study ,Hepatology ,business.industry ,Fatty liver ,Endoscopy ,medicine.disease ,Treatment Outcome ,business - Abstract
Obesity and its associated comorbidities are rapidly increasing in the US population. Therefore, metabolic associated fatty liver disease (MAFLD), previously known as nonalcoholic fatty liver disease (NAFLD), has become a leading indication for liver transplantation. Lifestyle modifications as a sole therapy have been insufficient to reduce the burden of chronic liver disease secondary to MAFLD. Endoscopic bariatric interventions (EBI) appear to be safe and effective therapies for obesity and chronic liver disease secondary to MAFLD. Gastric EBI include endoscopic sleeve gastroplasty (ESG) and intragastric balloons (IGB). Small bowel EBI are also evolving in the field of bariatric endoscopy.
- Published
- 2022
18. Diagnostic challenges and risk stratification of hepatocellular adenoma
- Author
-
Dana Balitzer and Sanjay Kakar
- Subjects
Pathology ,medicine.medical_specialty ,Histology ,Beta-catenin ,biology ,business.industry ,Focal nodular hyperplasia ,Hepatocellular adenoma ,medicine.disease ,Chronic liver disease ,digestive system diseases ,Pathology and Forensic Medicine ,Hepatocellular carcinoma ,Risk stratification ,biology.protein ,Medicine ,business - Abstract
Hepatocellular adenomas (HCA) are rare hepatocellular neoplasms which usually arise in non-cirrhotic liver, although rarely can arise in the background of chronic liver disease. While the majority of hepatocellular adenoma (HCA) are benign and may be managed conservatively, complications like hemorrhage and transformation to hepatocellular carcinoma (HCC) can occur. Risk stratification based on a combination of clinical, radiologic, histologic, and molecular features is necessary for appropriate management. This review focuses on diagnostic challenges in the diagnosis of HCA and its distinction from other hepatocellular proliferations such as focal nodular hyperplasia (FNH), hepatocellular carcinoma (HCC) and hepatocellular nodules in other clinical setting.
- Published
- 2022
19. Management of Thrombocytopenia and Coagulopathy in Patients with Chronic Liver Disease Undergoing Therapeutic Endoscopic Interventions
- Author
-
Lawrence S. Friedman and Jay Luther
- Subjects
Liver Cirrhosis ,Prothrombin time ,Hemostasis ,medicine.medical_specialty ,Cirrhosis ,Hepatology ,medicine.diagnostic_test ,business.industry ,Liver Diseases ,Blood Coagulation Disorders ,Chronic liver disease ,medicine.disease ,Thrombocytopenia ,Clinical trial ,Liver disease ,medicine ,Coagulopathy ,Humans ,Fresh frozen plasma ,Intensive care medicine ,business - Abstract
Management of coagulopathy in patients with advanced liver disease undergoing therapeutic endoscopic procedures is complex. Improvements in the understanding of hemostasis at a physiologic level have highlighted the inaccuracy of currently available clinical tests, like platelet count and prothrombin time, in estimating hemostasis in patients with cirrhosis. With identification of novel factors that contribute to bleeding risk in patients with cirrhosis, there is a dearth of clinical trial data that account for all potentially relevant factors and that examine interventions to reduce bleeding risk. Precise recommendations regarding transfusion strategies based on hemostatic test results in patients with cirrhosis are impractical.
- Published
- 2022
20. Inverse Association of Telomere Length With Liver Disease and Mortality in the US Population
- Author
-
Abhishek A. Mangaonkar, Alejandro Ferrer, Patrick S. Kamath, Joseph C. Ahn, Mrinal M. Patnaik, Douglas A. Simonetto, Puru Rattan, Daniel D. Penrice, and Vijay H. Shah
- Subjects
Adult ,Male ,medicine.medical_specialty ,National Health and Nutrition Examination Survey ,Population ,RC799-869 ,Chronic liver disease ,Gastroenterology ,Liver disease ,Young Adult ,Internal medicine ,Cause of Death ,medicine ,Leukocytes ,Humans ,education ,Telomere Shortening ,Aged ,Proportional Hazards Models ,Aged, 80 and over ,education.field_of_study ,Hepatology ,Proportional hazards model ,business.industry ,Liver Diseases ,Hazard ratio ,Original Articles ,Middle Aged ,Diseases of the digestive system. Gastroenterology ,medicine.disease ,Nutrition Surveys ,United States ,Cohort ,Disease Progression ,Linear Models ,Female ,Original Article ,Metabolic syndrome ,business - Abstract
Physiologic aging leads to attrition of telomeres and replicative senescence. An acceleration of this process has been hypothesized in the progression of chronic liver disease. We sought to examine the association of telomere length (TL) with liver disease and its impact on mortality risk. A cohort of 7,072 adults with leukocyte TL measurements from the National Health and Nutrition Examination Survey 1999‐2002 with mortality follow‐up through 2015 was analyzed. Liver disease was defined by aminotransferase levels and classified into etiology‐based and advanced fibrosis categories. Multivariable‐adjusted linear regression models estimated effect sizes, with 95% confidence intervals (CIs), of the presence of liver disease on TL. Cox regression models evaluated associations between TL and all‐cause mortality risk using adjusted hazard ratios (HRs). The cohort was representative of the US population with mean age 46.1 years and mean TL 5.79 kilobase pairs. No overall association between TL and liver disease was found; however, there was a significant negative association of TL and advanced liver fibrosis in individuals aged 65 and above. The liver disease cohort (HR 1.22, 95% CI 0.99‐1.51) and those with metabolic syndrome (HR 1.26, 95% CI 0.96‐1.67) had increased mortality risk with shorter TL. The relationship between TL and all‐cause mortality was stronger in women (HR 1.51, 95% CI 1.02‐2.23) and in non‐Hispanic Whites (HR 1.37, 95% CI 1.02‐1.84). Conclusion: Shortened leukocyte TL is independently associated with advanced liver disease at older ages, and with a higher risk of all‐cause mortality in those with liver disease. These associations reaffirm the need to better understand the role of telomeres in the progression of liver disease., We examined the association of peripheral telomere length with liver disease and assessed its impact on mortality using data from the National Health and Nutrition Examination Survey (NHANES). We discovered that shortened leukocyte telomere length is independently associated with advanced liver disease at older ages, and also with a higher risk of all‐cause mortality in those with liver disease.
- Published
- 2022
21. Native Vertebral Osteomyelitis in Patients with Staphylococcus Aureus Bacteremia
- Author
-
Raj Palraj, Elie F. Berbari, M. Rizwan Sohail, Wajeeha Tariq, Rommel Ramesh, Khawaja M Talha, Verda Arshad, Larry M. Baddour, Karen M. Fischer, and Hassan Ishaq
- Subjects
Adult ,Male ,Methicillin-Resistant Staphylococcus aureus ,Staphylococcus aureus ,medicine.medical_specialty ,Adolescent ,Bacteremia ,Chronic liver disease ,Coronary artery disease ,Internal medicine ,Diabetes mellitus ,Epidemiology ,medicine ,Humans ,Vertebral osteomyelitis ,Retrospective Studies ,business.industry ,Osteomyelitis ,General Medicine ,Middle Aged ,Staphylococcal Infections ,medicine.disease ,Cohort ,Female ,business - Abstract
Background : The purpose of the study was to assess the epidemiology, risk factors and outcomes of native vertebral osteomyelitis (NVO) in patients with Staphylococcus aureus bacteremia (SAB). Methods : A retrospective institutional review was conducted at Mayo Clinic, Minnesota. Patients aged ≥ 18 years with SAB who developed NVO from January 1, 2006 to December 31, 2020 were included and 3-month follow-up data were abstracted. Data pertaining to patient demographics, risk factors and outcomes were recorded using REDCap. A 1:2 nested case-control analysis was performed, and controls were matched according to age, sex and year of SAB diagnosis. Results : A total of 103 patients had NVO. A majority (60.2%) of patients was male, with a median age of 62.0 years. Thirty-one (30.1%) cases were caused by methicillin-resistant S. aureus (MRSA). The lumbar spine was most commonly (57.6%) and the most commonly reported comorbid conditions included diabetes mellitus (36.9%) and coronary artery disease (27.2%). Mortality at three-month follow-up was 18.6%. Nested case-control analysis revealed that injection drug use (IDU) and tobacco consumption were significant risk factors associated with NVO, while chronic hemodialysis and chronic liver disease (CLD) were associated with a decreased risk of NVO. Conclusions : Atherosclerotic vascular disease was prominent in our contemporary cohort with NVO in the setting of SAB. Diabetes mellitus, tobacco consumption, older age and male sex likely contributed to this profile. Because IDU was associated with NVO, an increased number of cases should be anticipated among patients with IDU given the ongoing opioid epidemic in the United States.
- Published
- 2022
22. Pre-morbidity and COVID-19 disease outcomes in Pakistani population: A cross-sectional study
- Author
-
Kaleem Ullah Toori, Muhammad Arsalan Qureshi, and Asma Chaudhry
- Subjects
medicine.medical_specialty ,business.industry ,Cross-sectional study ,General Medicine ,Disease ,medicine.disease ,Chronic liver disease ,disease severity (asymptomatic ,Asymptomatic ,mortality ,Corona Virus Induced Disease (COVID-19) ,invasive ventilation ,Internal medicine ,Diabetes mellitus ,medicine ,Chi-square test ,moderate and severe) ,mild ,Original Article ,medicine.symptom ,business ,Depression (differential diagnoses) ,Kidney disease ,pre-morbidities - Abstract
Objectives: To identify association of underlying pre-morbidities with disease severity and mortality in hospitalized patients with Corona virus disease 2019. Methods: Total 884 COVID RT-PCR positive patients admitted to KRL Hospital Islamabad from April 2020 to August 2020 were included in this cross-sectional study. Pre-morbidities recorded were hypertension, diabetes mellitus, ischemic heart disease, chronic respiratory disease, chronic kidney disease, chronic liver disease, chronic neuro-psychiatric conditions (stroke and depression) and malignancy. Oxygen requirement, requirement of invasive ventilation, and outcome (recovered versus died) was documented. WHO categories for disease severity were used. Demographic profile and symptoms were also noted. SPSS 22 was used for data analysis. Pearson’s Chi square test was used to see association between pre-morbidities and disease severity categories, oxygen requirement, invasive ventilation and outcome. Pearson’s correlation was applied to analyze the correlation between individual pre-morbidities and disease severity categories. P-value < 0.05 was considered statistically significant. Results: The mean age was 40 ± 12.21 years with 98.5% being males. Majority patients (74.8%) were asymptomatic. Fever was the most common symptom. Diabetes mellitus and hypertension were the most commonly recorded co-morbidity. Significant correlation (p-value < 0.05) was found between the presence of underlying pre-morbidities and disease severity as well as oxygen requirement, requirement of invasive ventilation and mortality. Conclusion: Results are compatible with worldwide studies and underlying pre-morbidities are convincing risk factors for disease severity and mortality. doi: https://doi.org/10.12669/pjms.38.1.4235 How to cite this:Toori KU, Qureshi MA, Chaudhry A. Pre-morbidity and COVID-19 disease outcomes in Pakistani population: A cross-sectional study. Pak J Med Sci. 2022;38(1):287-292. doi: https://doi.org/10.12669/pjms.38.1.4235 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
- Published
- 2022
23. Acute hepatitis E virus superinfection increases mortality in patients with cirrhosis
- Author
-
Ho Jin Son, Hee Jin Kim, Jae Min Lee, Jin-Kyu Cho, Hyun Jin Kim, Sang-Soo Lee, Jungwoo Choi, Ra Ri Cha, Hankyu Jeon, Woon Tae Jung, and Ok-Jae Lee
- Subjects
Liver Cirrhosis ,medicine.medical_specialty ,Cirrhosis ,Infectious and parasitic diseases ,RC109-216 ,medicine.disease_cause ,Gastroenterology ,Virus ,Internal medicine ,medicine ,Hepatitis E virus ,Humans ,In patient ,Mortality ,Acute hepatitis E ,business.industry ,Research ,Chronic liver disease ,Prognosis ,medicine.disease ,Hepatitis E ,Acute-on-chronic liver failure ,Infectious Diseases ,Superinfection ,business - Abstract
Background Although acute hepatitis E is not fatal in healthy individuals, it is unclear whether hepatitis E superinfection increases the mortality in patients with pre-existing liver disease. Thus, we investigated the prognosis of patients with acute hepatitis E according to their cirrhosis diagnosis, and the prognosis according to the development of acute-on-chronic liver failure (ACLF) in patients with cirrhosis and chronic liver disease (CLD). Methods This study included 74 consecutive patients who were diagnosed with acute viral hepatitis E between January 2007 and December 2019. Of them, 39 patients without CLD, 13 patients with non-cirrhotic CLD, and 22 patients with cirrhotic CLD were analyzed. Results Among the 74 patients with HEV infection, 7 (9.5%) died within 180 days: 5 with underlying cirrhosis (71.4%) and 2 without cirrhosis (28.6%). The 180-day mortality was significant higher for patients with cirrhosis than for patients without cirrhosis (22.7% vs. 3.8%, P = 0.013). The age- and sex-adjusted proportional-hazard model revealed an approximately eightfold increase in the 180-day mortality risk in patients with cirrhosis compared to patients without cirrhosis. In addition, development of hepatitis E virus-related ACLF due to acute liver function deterioration in patients with pre-existing CLD or cirrhosis worsened the 180-day mortality rate. Conclusions Our findings suggest that the acute hepatitis E mortality rate was low in healthy individuals but higher in patients with cirrhosis, and especially high in those with ACLF.
- Published
- 2022
24. Frequency of non-alcoholic fatty liver disease (NAFLD) and its associated risk factors among Type-2 diabetics
- Author
-
Muhammad Uthman Ahmed, Muhammad Aasim, Azeem Taj, Alia Ali, Elsa Tabrez, and Muhammad Joher Amin
- Subjects
medicine.medical_specialty ,medicine.diagnostic_test ,business.industry ,Type-2 Diabetes ,Fatty liver ,nutritional and metabolic diseases ,General Medicine ,Type 2 diabetes ,medicine.disease ,Chronic liver disease ,Obesity ,BMI ,Internal medicine ,NAFLD ,Hyperlipidemia ,medicine ,Original Article ,Lipid profile ,business ,Dyslipidemia ,Glycemic - Abstract
Objectives: To determine the frequency of Non-Alcoholic Fatty Liver Disease (NAFLD) and its associated risk factors among Type-2 Diabetic patients. Methods: This cross-sectional study was conducted in Diabetic Clinic of Shaikh Zayed Postgraduate Medical Institute Lahore from September 2019-February 2020. Type-2 diabetics regardless of age were divided into two groups, one with fatty liver disease and the other without this, evaluated by Abdominal Ultrasonography and were further evaluated by measurement of BMI, obesity, HbA1c and lipid profile. Exclusion criteria were patients having history of or currently taking alcohol, chronic Liver Disease of any cause and intake of hepatotoxic drugs. Qualitative measures were compared between groups by using Chi-square test. Binary logistic regression was used to see the association of factors with fatty liver disease. P-value ≤ 0.05 was considered significant. Results: A total of 185 subjects were included in the study with the mean age of 53.0±9.0 years. About 54.6% patients were diagnosed to have fatty liver disease. When compared the cases with and without fatty liver disease, age and HDL cholesterol had no significant difference between groups while other measures like BMI, TGs & cholesterol levels, ALT and AST were significantly higher among cases with NAFLD. BMI >24.5, HbA1c >7.0 and ALT >40.0 can predict NAFLD among Type-2 diabetic patients with 96.8% accuracy. Conclusion: There is high prevalence of NAFLD among Type-2 diabetic patients and strong association between Type-2 diabetics with NAFLD and risk factors like; obesity, high HbA1c, hyperlipidemia and high ALT. Therefore, early recognition by ultrasonography in high risk patients and intervention like life style modification, maintenance of healthy weight, obesity prevention, treatment of dyslipidemia and good glycemic control should be achieved in such subjects and can prevent NAFLD. doi: https://doi.org/10.12669/pjms.38.1.4968 How to cite this:Ali A, Amin MJ, Ahmed MU, Taj A, Aasim M, Tabrez E. Frequency of non-alcoholic fatty liver disease (NAFLD) and its associated risk factors among Type-2 diabetics. Pak J Med Sci. 2022;38(1):28-33. doi: https://doi.org/10.12669/pjms.38.1.4968 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
- Published
- 2022
25. [18F]MAGL-4-11 positron emission tomography molecular imaging of monoacylglycerol lipase changes in preclinical liver fibrosis models
- Author
-
Wenyu Lin, Qingzhen Yu, Tuo Shao, Mikhail Papisov, Andre J Jeyarajan, Jiahui Chen, Jian Rong, Zhen Chen, Lee Josephson, Steven H. Liang, Steve Rwema, Vasily Belov, Xiaoyun Deng, Raymond T. Chung, and Hualong Fu
- Subjects
Cirrhosis ,Chemistry ,Liver fibrosis ,PET imaging ,RM1-950 ,Pharmacology ,medicine.disease ,Chronic liver disease ,Endocannabinoid system ,Proinflammatory cytokine ,Monoacylglycerol lipase ,[18F]MAGL-4-11 ,In vivo ,Fibrosis ,MAGL ,medicine ,Hepatic stellate cell ,Original Article ,Therapeutics. Pharmacology ,General Pharmacology, Toxicology and Pharmaceutics - Abstract
Monoacylglycerol lipase (MAGL) is a pivotal enzyme in the endocannabinoid system, which metabolizes 2-arachidonoylglycerol (2-AG) into the proinflammatory eicosanoid precursor arachidonic acid (AA). MAGL and other endogenous cannabinoid (EC) degrading enzymes are involved in the fibrogenic signaling pathways that induce hepatic stellate cell (HSC) activation and ECM accumulation during chronic liver disease. Our group recently developed an 18F-labeled MAGL inhibitor ([18F]MAGL-4-11) for PET imaging and demonstrated highly specific binding in vitro and in vivo. In this study, we determined [18F]MAGL-4-11 PET enabled imaging MAGL levels in the bile duct ligation (BDL) and carbon tetrachloride (CCl4) models of liver cirrhosis; we also assessed the hepatic gene expression of the enzymes involved with EC system including MAGL, NAPE-PLD, FAAH and DAGL that as a function of disease severity in these models; [18F]MAGL-4-11 autoradiography was performed to assess tracer binding in frozen liver sections both in animal and human. [18F]MAGL-4-11 demonstrated reduced PET signals in early stages of fibrosis and further significantly decreased with disease progression compared with control mice. We confirmed MAGL and FAAH expression decreases with fibrosis severity, while its levels in normal liver tissue are high; in contrast, the EC synthetic enzymes NAPE-PLD and DAGL are enhanced in these different fibrosis models. In vitro autoradiography further supported that [18F]MAGL-4-11 bound specifically to MAGL in both animal and human fibrotic liver tissues. Our PET ligand [18F]MAGL-4-11 shows excellent sensitivity and specificity for MAGL visualization in vivo and accurately reflects the histological stages of liver fibrosis in preclinical models and human liver tissues., Graphical abstract This study comprehensively evaluated [18F]MAGL-4-11, a 18F-labeled monoacylglycerol lipase (MAGL) radioligand, in preclinical liver fibrosis models and human specimens, which would facilitate drug development in MAGL-related liver fibrosis disease.Image 1
- Published
- 2022
26. Safety Assessment of Autologous Stem Cell Combination Therapy in Patients With Decompensated Liver Cirrhosis: A Pilot Study
- Author
-
Santosh Darisetty, Jagdeesh Rampal Singh, Pragati Naik, Pavan Kumar Pondugala, Vemula V. Krishna, Anuradha Sekharan, Guduru V. Rao, Pramod Kumar, Anand V. Kulkarni, Ganesh Jaishetwar, Rajesh Gupta, Mithun Sharma, Padaki Nagaraja Rao, Duvurr N. Reddy, Sasikala Mitnala, Fatima Syeda, Nitin Jagtap, and Shashidhar Jaggaihgari
- Subjects
Cirrhosis ,Hepatology ,Combination therapy ,business.industry ,Mesenchymal stem cell ,Leukapheresis ,Pharmacology ,Chronic liver disease ,medicine.disease ,03 medical and health sciences ,Haematopoiesis ,0302 clinical medicine ,medicine.anatomical_structure ,030220 oncology & carcinogenesis ,medicine ,Original Article ,030211 gastroenterology & hepatology ,Bone marrow ,Stem cell ,business - Abstract
Background Haematopoietic stem cell (HSC) infusion has demonstrated short-term improvement in liver functions in patients with chronic liver disease. The combination of HSC with mesenchymal stem cells (MSCs), which has an immunomodulatory effect, may augment the effects and enhance the duration of improvements on liver functions. The aim of the present study was to assess the safety of infusing the combination of autologous HSCs and MSCs in decompensated liver cirrhosis. Methods In phase I of the study, in vitro assessment was performed to observe the effect of coculturing MSCs with HSCs on their viability and cytokine profiles. Phase II of the study was to assess the safety of combination of stem cell infusions. Bone marrow (50 ml) was aspirated for MSC isolation and expansion using standard protocol. Patients received subcutaneous doses (n = 5) of granulocyte colony-stimulating factor (G-CSF) for stem cell mobilization followed by leukapheresis for harvesting HSCs using CliniMacs. HSCs and MSCs were infused through the hepatic artery under fluoroscopic guidance and were monitored for any adverse effects. Results In vitro studies revealed 94% viable HSCs in coculture similar to monoculture. HSCs released only interleukin (IL)-8, whereas MSCs secreted IL-8 and IL-6 in monocultures, and both IL-8 and IL-6 were secreted in coculture. G-CSF administration– and bone marrow aspiration–related complications were not observed. Infusion of the cells through the hepatic artery was safe, and no postprocedural complications were noted. Conclusion The combination of autologous HSC and MSC infusion is a safe procedure in patients with decompensated liver cirrhosis, and the outcomes needed to be assessed in larger studies. Trial number NCT04243681 .
- Published
- 2022
27. Acute upper gastrointestinal bleeding due to portal hypertension in children: What is the best timing of endoscopy?
- Author
-
Sylvia Costa Lima Farhat, Silvia Almeida Cardoso, Marcela Preto-Zamperlini, Claudio Schvartsman, Ana Cristina Aoun Tannuri, and Fernanda Paixão Silveira Bello
- Subjects
Male ,medicine.medical_specialty ,Time Factors ,Adolescent ,medicine.medical_treatment ,Logistic regression ,Chronic liver disease ,Endoscopy, Gastrointestinal ,Time-to-Treatment ,Patient Admission ,Internal medicine ,Hypertension, Portal ,medicine ,Sclerotherapy ,Humans ,Child ,Retrospective Studies ,Hepatology ,medicine.diagnostic_test ,business.industry ,Medical record ,Gastroenterology ,Infant ,Retrospective cohort study ,Acute upper gastrointestinal bleeding ,medicine.disease ,Endoscopy ,Treatment Outcome ,Child, Preschool ,Acute Disease ,Portal hypertension ,Female ,Emergency Service, Hospital ,Gastrointestinal Hemorrhage ,business - Abstract
To compare initial clinical/laboratory parameters and outcomes of mortality/rebleeding of endoscopy performed12 h(early UGIE) versus endoscopy performed after 12-24h(late UGIE) of ED admission in children with acute upper gastrointestinal bleeding(AUGIB) due to portal hypertension.This is a retrospective cohort study. From January 2010 to July 2017, medical records of all children admitted to a tertiary care hospital with AUGIB due to portal hypertension were reviewed until 60 days after ED admission.A total of 98 ED admissions occurred from 73 patients. Rebleeding was identified in 8/98(8%) episodes, and 9 deaths were observed. UGIE was performed in 92(94%) episodes, and 53(58%) of them occurred within 12 h of ED admission. Episodes with early UGIE and late UGIE were similar in terms of history/complaints/laboratory data at admission, chronic liver disease associated, AUGIB duration, and initial management. No statistically significant associations were found between early UGIE and the outcomes of death/rebleeding and prevalence of endoscopic hemostatic treatment (band ligation or sclerotherapy) compared to late UGIE. In the multivariable logistic regression model, the endoscopic hemostatic treatment showed a negative association with early UGIE(OR=0.33;95%CI=0.1-0.9;p = 0.04).This study suggests that in pediatric patients with AUGIB and portal hypertension, UGIE may be performed after 12-24 h without harm to the patient, facilitating better initial clinical stabilization/treatment and optimization of resources.
- Published
- 2022
28. Are we missing varices by implementing Baveno-VI recommendation of not screening patients with Compensated Advanced Chronic Liver Disease?
- Author
-
Nimrah Bader, Faiza Ali, Tazeen Rasheed, and Bader Faiyaz Zuberi
- Subjects
Compensated Advanced Chronic Liver Disease ,medicine.medical_specialty ,Varices ,Varix ,Cirrhosis ,Receiver operating characteristic ,business.industry ,General Medicine ,Creative commons ,Chronic liver disease ,medicine.disease ,Baveno-VI ,Gastroenterology ,Esophageal varices ,Internal medicine ,Gastroscopy ,Medicine ,Cutoff ,Original Article ,business - Abstract
Objectives: This study aimed to validate Baveno-VI recommendations for variceal screening in cACLD in our region and proposed our own cutoff values. Methods: Prospective cross-sectional study was conducted on cACLD patients from August 2020 till April 2021. Patients segregated into Group-A, having Liver stiffness measurement (LSM) of ≥ 20 kPa and platelet of ≤ 150 × 109 cells/L; and Group-B having LSM of < 20 kPa and PLT of > 150 × 109 cells/L. Gastroscopic findings were segregated into three categories, VNT, Varices Not Needing Treatment (VNNT) and No Varix (NV). ROC plots were generated for LSM and Platelet for VNT for sensitivity, specificity, Negative and Positive Predictive Values were calculated. Results: A total of 134 patients of cACLD were included. Group-A had 72 (53.7%) patients and Group-B had 62 (46.3%) patients. Group-A had 6 (8.3%) NV; 18 (25.0%) VNNT and 48 (66.7%) VNT. Group-B had 26 (41.9%) NV, 24 (38.7%) VNNT and 12 (19.4%) VNT. The sensitivity of 66.7%, specificity of 80.6% and NPV of 67.56% was obtained. Thus 19.4% VNT were missed on following Baveno VI recommendations. ROC in our study suggested cutoff value of 11.5 kPa with sensitivity of 100% and 1-sepcifity pf 78% (AUROC = 0.865; p < .001) of LSM below which screening gastroscopy could be avoided. The positive and negative predicted values for 84.85% and 100% respectively. Cut off value of platelet count for VNNT came out to be ≥ 97.5 × 109 cells/L with AUROC 0.891 (p < .001), having sensitivity of 100 % and 1-specificity of 83.3%. Conclusions: Substantial number of VNT in cACLD patients are missed by following Baveno-VI recommendations and these needs to be revised on regional basis. List If Abbreviations: AASLD: American Association for Study of Liver Diseases (AASLD), AUROC: Area Under Receiver Operating Characteristic, cACLD: Compensated Advance Chronic Liver Disease (cACLD), CTP: Child-Turcotte-Pugh, DCLD: Decompensated Chronic Liver Disease (DCLD), EV: Esophageal Varices, KPa: Kilo Pascal, LSM: Liver stiffness measurement (LSM), NPV: Negative Predictive Value, NV: No Varix (NV)., PPV: Positive Predictive Value, ROC: Receiver Operating Characteristic, VNNT: Varices Not Needing Treatment (VNNT) and VNT: Varices Needing Treatment (VNT). How to cite this:Ali FS, Bader N, Zuberi BF, Rasheed T. Are we missing varices by implementing Baveno-VI recommendation of not screening patients with Compensated Advanced Chronic Liver Disease? Pak J Med Sci. 2022;38(1):1-8. doi: https://doi.org/10.12669/pjms.38.1.4796 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
- Published
- 2022
29. PNPLA3 is the dominant SNP linked to liver disease severity at time of first referral to a tertiary center
- Author
-
Felix Stickel, Michael Strasser, Elmar Aigner, Lorenz Balcar, Hannes Oberkofler, Bernhard Paulweber, David Niederseer, Leonora Datz, Georg Semmler, Alexandra Feldman, Christian Datz, and Stephan Zandanell
- Subjects
Genetic Markers ,Male ,medicine.medical_specialty ,Cirrhosis ,17-Hydroxysteroid Dehydrogenases ,Genotype ,Single-nucleotide polymorphism ,Disease ,Chronic liver disease ,Polymorphism, Single Nucleotide ,Severity of Illness Index ,Gastroenterology ,Liver disease ,Non-alcoholic Fatty Liver Disease ,Risk Factors ,Internal medicine ,Humans ,Medicine ,Referral and Consultation ,Alleles ,Retrospective Studies ,Hepatology ,business.industry ,Liver Diseases ,Fatty liver ,Membrane Proteins ,Middle Aged ,medicine.disease ,Cross-Sectional Studies ,Liver ,alpha 1-Antitrypsin ,Chronic Disease ,Phospholipases A2, Calcium-Independent ,Female ,business ,Acyltransferases ,TM6SF2 - Abstract
Background Single nucleotide polymorphisms (SNPs) in genes including PNPLA3, TM6SF2, HSD17B13 and SERPINA1 have been identified as risk modifiers of progression in chronic liver disease (CLD). However, it is unclear whether genotyping for these risk variants is useful in clinical routine. Methods Liver disease severity was assessed by liver stiffness measurement (LSM) and by presence of clinical manifestations of advanced-chronic liver disease (ACLD) in 779 consecutive CLD patients at the time of referral to a tertiary center. The associations of risk variants with CLD severity were calculated individually and in a combined model using a polygenic risk-score. Results Non-alcoholic fatty liver disease (NAFLD) was the most common etiology (n = 511, 65.6%), and ACLD was present in 217 (27.9%) patients. The PNPLA3-G-allele remained independently associated with higher LSM (adjusted-B: 2.508 [95%CI: 0.887–4.130], P = 0.002) or the presence of ACLD (aOR: 1.562 [95%CI: 1.097–2.226], P = 0.013). SERPINA1-Z-allele was also independently associated with LSM (adjusted-B: 4.558 [95%CI: 1.182–7.934], P = 0.008), while the other risk alleles did not attain statistical significance. Combining these risk alleles into a polygenic risk-score was significantly associated with LSM (adjusted-B: 0.948 [95%CI: 0.153–1.743], P = 0.020). Conclusion PNPLA3 risk-variants are linked to liver disease severity at the time of first referral to an outpatient hepatology clinic.
- Published
- 2022
30. Association Between ACOX1 and NRF1 Gene Expression and Hepatitis B and C Virus Infections and Hepatocellular Carcinoma in Liver Transplant Patients (Shiraz, Iran)
- Author
-
Gholamreza Motalleb, Ramin Yaghobi, and Ehsan Nabi Abdolyousefi
- Subjects
Hepatitis B virus ,medicine.medical_specialty ,Carcinoma, Hepatocellular ,Hepatitis C virus ,medicine.medical_treatment ,Gene Expression ,Hepacivirus ,Iran ,Liver transplantation ,medicine.disease_cause ,Chronic liver disease ,Gastroenterology ,Virus ,Internal medicine ,ABO blood group system ,medicine ,Humans ,Transplantation ,business.industry ,Liver Neoplasms ,Hepatitis B ,medicine.disease ,Hepatitis C ,Liver Transplantation ,Cross-Sectional Studies ,Treatment Outcome ,Hepatocellular carcinoma ,Neoplasm Recurrence, Local ,business - Abstract
Objectives Liver transplantation is used to treat both patients with end-stage liver diseases and those with hepatocellular carcinoma; in Iran, these patients are commonly infected with hepatitis B and C viruses. In the present study, for the first time, we investigated the association between ACOX1 and NRF1 gene and protein expression and presence of hepatitis B virus, hepatitis C virus, and hepatocellular carcinoma in liver transplant patients in South-Central Iran. Materials and methods In this cross-sectional study, we included 200 patients who were seen between 2008 and 2017 for liver transplant at the Namazi Hospital, Shiraz University of Medical Sciences (Shiraz, Iran). All patients received liver grafts from brain dead donors. Donors and recipients were unrelated. ABO compatibility blood group analyses for donor-recipient pairs were conducted. Liver transplant recipients were divided into 3 different groups: hepatitis B virus infected, hepatitis C virus infected, and presence of hepatocellular carcinoma. We also had a control group that included 30 healthy individuals. NRF1 and ACOX1 gene expression levels were evaluated using the SYBER green real-time polymerase chain reaction method. NRF1 and ACOX1 protein expression levels were evaluated using enzymelinked immunosorbent analyses. We used SPSS software for statistical analyses (version 19.0). Results NRF1 gene expression was increased in all 3 liver transplant recipient groups compared with the control group (not significant, P > .05). Furthermore, ACOX1 gene expression was decreased in all patients compared with control (P > .05). However, we found ACOX1 and NRF1 protein expression to be significantly decreased in all 3 liver transplant recipients groups compared with the control group (P Conclusions NRF1 and ACOX1 genes and their protein expressions could affect the development of chronic liver disease.
- Published
- 2022
31. Dietary Risks for Liver Mortality in NAFLD: Global Burden of Disease Data
- Author
-
Janus Ong, Seema Mir, Saleh A. Alqahtani, Youssef Younossi, Zobair M. Younossi, and James Paik
- Subjects
Sociodemographic Factors ,Physiology ,Renal function ,RC799-869 ,Chronic liver disease ,Global Burden of Disease ,Age Distribution ,Non-alcoholic Fatty Liver Disease ,Nonalcoholic fatty liver disease ,Medicine ,Humans ,chemistry.chemical_classification ,Hepatology ,business.industry ,Cardiometabolic Risk Factors ,Original Articles ,Stepwise regression ,Diseases of the digestive system. Gastroenterology ,medicine.disease ,Diet ,Blood pressure ,chemistry ,Red meat ,Original Article ,business ,Body mass index ,Polyunsaturated fatty acid - Abstract
Nonalcoholic fatty liver disease (NAFLD) is a common but complex chronic liver disease, driven by environmental and genetic factors. We assessed metabolic and dietary risk factor associations with NAFLD liver mortality using the Global Burden of Disease (GBD) 2017 data. NAFLD liver deaths were calculated (per 100,000) as age-standardized rates (ASRs) from 195 countries and territories (21 GBD regions; 7 GBD superregions). Dietary risks included low intake of fruits, vegetables, legumes, whole grains, nuts/seeds, milk, fiber, calcium, seafood omega-3 fatty acids, and polyunsaturated fatty acids, and high intake of red meat, processed meat, sugar-sweetened beverages, trans fatty acids, and sodium. Metabolic risks included high low-density lipoprotein cholesterol, systolic blood pressure (BP), fasting glucose (FG), body mass index (BMI), as well as low bone mineral density and impaired kidney function (IKF). Socio-demographic index (SDI)-adjusted partial Spearman correlation coefficients and multivariable generalized linear regression models/bidirectional stepwise selection (significance level for entry, 0.2; for stay, 0.05) determined the associations. The ASR for NAFLD liver deaths was 2.3 per 100,000 (2017) and correlated with dietary risk factors (0.131, -0.010-0.267) and metabolic risk factors (SDI-adjusted = 0.225, 95% CI 0.086-0.354). High intake of sugar-sweetened beverages and red meat (0.358, 0.229-0.475; 0.162, 0.022-0.296), and low intake of nuts/seed and milk (0.154, 0.014-0.289; 0.145, 0.004-0.280) was significant for NAFLD liver deaths. Other risk factors for liver death included IKF (0.402, 0.276-0.514), increased BMI (0.353, 0.223-0.407), FG (0.248, 0.111-0.376), and BP (0.163, 0.022-0.297). High intake of trans fatty acids (2.84% increase [1.65%-4.03%]) was the largest associated risk of NAFLD liver deaths. In addition to metabolic risks, dietary risks independently drive the global burden of NAFLD-related liver mortality. Conclusion: These data provide additional support for policies to improve dietary environment for NAFLD burden reduction.
- Published
- 2022
32. Oral Cyanobacteria and Hepatocellular Carcinoma
- Author
-
Xuemei Zhu, Joseph K. Lim, Melinda L. Irwin, Brenda Y. Hernandez, Herbert Yu, Xiaomei Ma, Harvey A. Risch, Lingeng Lu, Robert S. Brown, Zhanwei Wang, Karen Pawlish, Antoinette M. Stroup, Linda L. Wong, and Tamar H. Taddei
- Subjects
Adult ,Male ,medicine.medical_specialty ,Carcinoma, Hepatocellular ,Epidemiology ,Hepatitis C virus ,Type 2 diabetes ,Cyanobacteria ,Chronic liver disease ,medicine.disease_cause ,Gastroenterology ,Article ,Risk Factors ,Internal medicine ,medicine ,Humans ,Risk factor ,Aged ,Aged, 80 and over ,Hepatitis B virus ,Mouth ,business.industry ,Liver Neoplasms ,Fatty liver ,Middle Aged ,medicine.disease ,United States ,digestive system diseases ,Oncology ,Case-Control Studies ,Hepatocellular carcinoma ,Female ,business ,Liver cancer - Abstract
Background: Gut microbial alterations have been linked to chronic liver disease and hepatocellular carcinoma (HCC). The role of the oral microbiome in liver cancer development has not been widely investigated. Methods: Bacterial 16S rRNA sequences were evaluated in oral samples from 90 HCC cases and 90 controls who were a part of a larger U.S. case–control study of HCC among patients diagnosed from 2011 to 2016. Results: The oral microbiome of HCC cases showed significantly reduced alpha diversity compared with controls (Shannon P = 0.002; Simpson P = 0.049), and beta diversity significantly differed (weighted Unifrac P = 0.004). The relative abundance of 30 taxa significantly varied including Cyanobacteria, which was enriched in cases compared with controls (P = 0.018). Cyanobacteria was positively associated with HCC [OR, 8.71; 95% confidence interval (CI), 1.22–62.00; P = 0.031] after adjustment for age, race, birthplace, education, smoking, alcohol, obesity, type 2 diabetes, Hepatitis C virus (HCV), Hepatitis B virus (HBV), fatty liver disease, aspirin use, other NSAID use, laboratory batch, and other significant taxa. When stratified by HCC risk factors, significant associations of Cyanobacteria with HCC were exclusively observed among individuals with negative histories of established risk factors as well as females and college graduates. Cyanobacterial genes positively associated with HCC were specific to taxa producing microcystin, the hepatotoxic tumor promotor, and other genes known to be upregulated with microcystin exposure. Conclusions: Our study provides novel evidence that oral Cyanobacteria may be an independent risk factor for HCC. Impact: These findings support future studies to further examine the causal relationship between oral Cyanobacteria and HCC risk.
- Published
- 2022
33. U-shaped relationship between urea level and hepatic decompensation in chronic liver diseases
- Author
-
Jimmy Che-To Lai, Vicki Wing-Ki Hui, Ken Liu, Henry Lik-Yuen Chan, Xinrong Zhang, Yee-Kit Tse, Terry Cheuk-Fung Yip, Huapeng Lin, Grace Lai-Hung Wong, and Vincent Wai-Sun Wong
- Subjects
medicine.medical_specialty ,Carcinoma, Hepatocellular ,Cirrhosis ,liver cirrhosis ,urea ,RC799-869 ,Chronic liver disease ,Gastroenterology ,chemistry.chemical_compound ,Internal medicine ,Nonalcoholic fatty liver disease ,medicine ,Humans ,hepatitis b ,Molecular Biology ,Hepatology ,Proportional hazards model ,business.industry ,Liver Neoplasms ,fibrosis ,Hazard ratio ,non-alcoholic fatty liver disease ,Diseases of the digestive system. Gastroenterology ,medicine.disease ,chemistry ,Hepatocellular carcinoma ,Urea ,Elasticity Imaging Techniques ,Original Article ,Transient elastography ,business ,Liver Failure - Abstract
Background/Aims: We aimed to determine the association between blood urea level and incident cirrhosis, hepatic decompensation, and hepatocellular carcinoma in chronic liver disease (CLD) patients.Methods: The association between blood urea level and liver fibrosis/liver-related events were evaluated on continuous scale with restricted cubic spline curves based on generalized additive model or Cox proportional hazards models. Then, the above associations were evaluated by urea level within intervals.Results: Among 4,282 patients who had undergone liver stiffness measurement (LSM) by transient elastography, baseline urea level had a U-shaped association with LSM and hepatic decompensation development after a median follow-up of 5.5 years. Compared to patients with urea of 3.6–9.9 mmol/L, those with urea ≤3.5 mmol/L (adjusted hazard ratio [aHR], 4.15; 95% confidence interval [CI], 1.68–10.24) and ≥10 mmol/L (aHR, 5.22; 95% CI, 1.86–14.67) had higher risk of hepatic decompensation. Patients with urea ≤3.5 mmol/L also had higher risk of incident cirrhosis (aHR, 3.24; 95% CI, 1.50–6.98). The association between low urea level and incident cirrhosis and hepatic decompensation was consistently observed in subgroups by age, gender, albumin level, and comorbidities. The U-shaped relationship between urea level and LSM was validated in another population screening study (n=917). Likewise, urea ≤3.5 mmol/L was associated with a higher risk of incident cirrhosis in a territory-wide cohort of 12,476 patients with nonalcoholic fatty liver disease at a median follow-up of 9.9 years (aHR, 1.27; 95% CI, 1.03–1.57).Conclusions: We identified a U-shaped relationship between the urea level and liver fibrosis/incident cirrhosis/hepatic decompensation in patients with CLD.
- Published
- 2022
34. Beneficial Effects of Dietary Polyphenols in the Prevention and Treatment of NAFLD: Cell-Signaling Pathways Underlying Health Effects
- Author
-
Andrés Bustamante, Verónica Sambra, Luis A. Videla, Rodrigo Valenzuela, Francisca Echeverría, and Daniela Álvarez
- Subjects
Pharmacology ,business.industry ,Organic Chemistry ,Fatty liver ,Polyphenols ,medicine.disease ,medicine.disease_cause ,Chronic liver disease ,Biochemistry ,Antioxidants ,Insulin resistance ,Liver ,Non-alcoholic Fatty Liver Disease ,Drug Discovery ,Nonalcoholic fatty liver disease ,Lipogenesis ,medicine ,Humans ,Molecular Medicine ,Steatohepatitis ,business ,Beta oxidation ,Oxidative stress ,Signal Transduction - Abstract
Background: Non-alcoholic fatty liver disease (NAFLD) is characterized by hepatic accretion of triacylglycerides in the absence of alcohol intake that may progress to steatohepatitis, fibrosis and cirrhosis, becoming the main cause of chronic liver disease. This article discusses recent data concerning the use of dietary polyphenols in the prevention and treatment of NAFLD in vitro, in vivo, and in clinical trials. Methods: Study searches were performed using the PubMed database from the National Library of Medicine-National Institutes of Health. Results: Polyphenols exert beneficial effects in NAFLD, with positive outcomes being related to body weight gain, insulin resistance, liver fat accumulation, oxidative stress, proinflammatory status, mitochondrial dysfunction and ER stress. Data reported for hydroxytyrosol suggest that the activation of the hepatic PPAR-α-FGF21-AMPK-PGC-1α signaling cascade is associated with fatty acid oxidation enhancement, de novo lipogenesis diminution and recovery of mitochondrial function, a contention that is supported by the actions of several polyphenols on specific components of this signaling pathway. Besides, polyphenols downregulate NF-κB, suppressing the pro-inflammatory state developed in NAFLD and upregulate liver Nrf2, increasing the cellular antioxidant potential. The latter feature of polyphenols is contributed by chelation of pro-oxidant trace elements, reduction of free radicals to stable forms and inhibition of free radical generating systems. Conclusion: Polyphenols are relevant bioactive compounds in terms of prevention and treatment of NAFLD, which exhibit low bioavailability and instability in biological systems that could limit their health effects. These drawbacks reinforce the necessity of further studies to improve the efficacy of polyphenol formulations for human interventions.
- Published
- 2022
35. Health‐related quality of life is dynamic in alcoholic hepatitis and responds to improvement in liver disease and reduced alcohol consumption
- Author
-
Qing Tang, Naga Chalasani, Craig Lammert, Archita P. Desai, Vijay H. Shah, Niharika Samala, Abhishek Madathanapalli, and Arun J. Sanyal
- Subjects
Adult ,Male ,medicine.medical_specialty ,Alcohol Drinking ,SF-36 ,media_common.quotation_subject ,Medicine (miscellaneous) ,Alcoholic hepatitis ,Toxicology ,Chronic liver disease ,Severity of Illness Index ,Article ,Liver disease ,Quality of life ,Surveys and Questionnaires ,Internal medicine ,Ascites ,medicine ,Humans ,Prospective Studies ,media_common ,Hepatitis, Alcoholic ,business.industry ,Middle Aged ,Abstinence ,medicine.disease ,Psychiatry and Mental health ,Quality of Life ,Female ,Analysis of variance ,medicine.symptom ,business ,Follow-Up Studies - Abstract
The impact of alcoholic hepatitis (AH) on health-related quality of life (HRQOL) remains inadequately described. We aimed to characterize HRQOL in AH and heavy drinkers (HD), and its associations with clinical variables and outcomes.This is a post hoc analysis of participants in the Translational Research and Evolving Alcoholic Hepatitis Treatment 001 study (NCT02172898). HRQOL was measured using Short Form Health Survey (SF-36). Mean SF-36 scores were compared in AH and HD with two-sample t-tests. Associations among clinical characteristics, 30-day mortality, and SF-36 mental and physical component scores (MC, PC) were investigated with generalized linear and logistic multivariate regression models. Trends of MC and PC scores were analyzed using one-way ANOVA.Participants with AH (n = 258) and HD (n = 181) were similar demographically. AH cases had a mean Model for End-stage Liver Disease (MELD) score of 23 (7). AH cases had lower PC scores [37 (10) vs. 48 (11), p 0.001] but higher MC scores [37 (13) vs. 32 (13), p 0.001]. MC scores were independently associated with age, male gender, and daily alcohol consumption; PC scores were independently associated with age, BMI, alanine aminotransferase concentration, alkaline phosphatase concentration, white blood cell counts, and the presence of ascites. With each 5-point decrease in the baseline PC score, the adjusted odds of dying within 30 days increased by 26.7% (95% CI 1% to 46%). Over time, HRQOL in AH improved (day 0 to day 180 delta PC score: 4.5 ± 1.7, p = 0.008; delta MC score: 9.8 ± 2.0, p 0.001). Participants with a MELD score15 by day 180 had greater increases in PC scores than those with MELD score ≥15 (delta PC score 7.1 ± 1.8 vs. -0.7 ± 2.3, p = 0.009), while those abstinent by day 180 had greater increases in MC scores than those who were not abstinent (delta MC score 9.1 ± 1.8 vs. 2.8 ± 2.4, p = 0.044).HRQOL is poor in AH and HD in a domain-specific pattern. Independent of MELD score, lower baseline HRQOL is associated with higher 30-day mortality. Over time, HRQOL improves with greater gains seen in individuals with improved MELD scores and those who were abstinent.
- Published
- 2021
36. Ductular reaction promotes intrahepatic angiogenesis through Slit2–Roundabout 1 signaling
- Author
-
Juan José Lozano, Pau Sancho-Bru, Javier Gallego, Delia Blaya, Mercedes Fernandez, Anna Moles, Albert Pol, Pere Ginès, Andrea Fernández-Vidal, Jian-Guo Geng, Julia Vallverdú, Teresa Rubio-Tomás, Ester Garcia-Pras, Ramon Bataller, Mar Coll, Beatriz Aguilar-Bravo, Elisa Pose, Celia Martínez-Sánchez, Isabel Graupera, Silvia Ariño, Instituto de Salud Carlos III, European Commission, National Institute on Alcohol Abuse and Alcoholism (US), Generalitat de Catalunya, European Foundation for Alcohol Research, Centro de Investigación Biomédica en Red Enfermedades Hepáticas y Digestivas (España), and Ministerio de Educación, Cultura y Deporte (España)
- Subjects
Alcoholic liver disease ,Angiogenesis ,Gene Expression ,Neovascularization, Physiologic ,Nerve Tissue Proteins ,Vascular Remodeling ,Chronic liver disease ,Article ,Mice ,Downregulation and upregulation ,Fibrosis ,medicine ,Animals ,Humans ,Receptors, Immunologic ,Liver Diseases, Alcoholic ,Liver injury ,Tube formation ,Wound Healing ,Neovascularization, Pathologic ,Hepatology ,Hepatitis, Alcoholic ,business.industry ,Stem Cells ,Patient Acuity ,medicine.disease ,Liver regeneration ,Up-Regulation ,Organoids ,Gene Ontology ,Liver ,Chronic Disease ,Disease Progression ,Cancer research ,Blood Vessels ,Intercellular Signaling Peptides and Proteins ,business ,Signal Transduction - Abstract
Background and aims: Ductular reaction (DR) expands in chronic liver diseases and correlates with disease severity. Besides its potential role in liver regeneration, DR plays a role in the wound-healing response of the liver, promoting periductular fibrosis and inflammatory cell recruitment. However, there is no information regarding its role in intrahepatic angiogenesis. In the current study we investigated the potential contribution of DR cells to hepatic vascular remodeling during chronic liver disease. Approach and results: In mouse models of liver injury, DR cells express genes involved in angiogenesis. Among angiogenesis-related genes, the expression of Slit2 and its receptor Roundabout 1 (Robo1) was localized in DR cells and neoangiogenic vessels, respectively. The angiogenic role of the Slit2-Robo1 pathway in chronic liver disease was confirmed in ROBO1/2-/+ mice treated with 3,5-diethoxycarbonyl-1,4-dihydrocollidine, which displayed reduced intrahepatic neovascular density compared to wild-type mice. However, ROBO1/2 deficiency did not affect angiogenesis in partial hepatectomy. In patients with advanced alcohol-associated disease, angiogenesis was associated with DR, and up-regulation of SLIT2-ROBO1 correlated with DR and disease severity. In vitro, human liver-derived organoids produced SLIT2 and induced tube formation of endothelial cells. Conclusions: Overall, our data indicate that DR expansion promotes angiogenesis through the Slit2-Robo1 pathway and recognize DR cells as key players in the liver wound-healing response., Supported by grants from Fondo de Investigación Sanitaria Carlos III (FIS), cofinanced by Fondo Europeo de Desarrollo Regional (FEDER), Unión Europea, “Una manera de hacer Europa” (FIS PI20/00765, PI17/00673, to P.S.-B; FIS 18-PI18/00862, to I.G and M.C); from the National Institute on Alcohol Abuse and Alcoholism (1U01AA026972-01 and AGAUR 2017-SGR-01456, to P.S.-B.); and from the European Foundation for Alcohol Research (EA1653, to P.S.-B.). M.C. is funded by the Ramon y Cajal program from the Ministerio de Ciencia e Innovación RYC2019-026662-I. P.G. is funded by the Agencia de Gestió d'Ajuts Universitaris i de Recerca 2014 SGR 708, Centro de Investigaciónen Red Enfermedades Hepáticas y Digestivas (CIBERehd), and Institució Catalana de Recerca i Estudis Avançats. S.A. received a grant from the Ministerio de Educación, Cultura y Deporte (FPU17/04992). B.A.-B. is funded by the Instituto de Salud Carlos III (FI16/00203)
- Published
- 2021
37. Attributable mortality of candidemia at a German tertiary hospital from 1997 to 2001 before the introduction of echinocandins
- Author
-
Philipp Koehler, Oliver A. Cornely, Harald Seifert, Jon Salmanton-García, and Yael Blankenheim
- Subjects
medicine.medical_specialty ,Antifungal Agents ,medicine.medical_treatment ,Dermatology ,Disease ,Chronic liver disease ,law.invention ,Tertiary Care Centers ,Echinocandins ,Risk Factors ,law ,Germany ,Internal medicine ,Amphotericin B ,Humans ,Medicine ,Hospital Mortality ,business.industry ,Incidence ,Incidence (epidemiology) ,Mortality rate ,Candidemia ,General Medicine ,medicine.disease ,Intensive care unit ,Infectious Diseases ,Case-Control Studies ,business ,Central venous catheter ,Fluconazole ,medicine.drug - Abstract
OBJECTIVES The relevance of candidemia has increased over the last decades due to higher incidence rates in an aging society. Studies on amphotericin B and fluconazole have shown high attributable mortality rates of 38% and 49% in the US. Incidence rates and locational factors might have an impact on the mortality rates at the University Hospital of Cologne (UHC), Germany. METHODS We performed a matched case-control study including 57 patients with candidemia, hospitalized at the UHC between 1st of July 1997 and 30th of June 2001. Controls were matched by age, sex, admission date, treatment on intensive care unit (ICU), number of days at risk, underlying diseases, surgical procedures, and the Charlson Comorbidity Index. RESULTS The incidence of candidemia was 3.5 per 10,000 admissions. For cases and controls, we observed in-hospital-mortality rates of 33.3% and 11.8%, and a 30-day mortality of 23.5% and 7.8%, respectively. The attributable mortality rate to candidemia was 21.5%, and at 30-days it was 15.7%. Underlying conditions were more frequent in cases than in controls, especially central venous catheter (80% vs. 33% p
- Published
- 2021
38. Viral hepatitis in children: what do we know in 2021?
- Author
-
Deirdre Kelly and Chayarani Kelgeri
- Subjects
Hepatitis ,medicine.medical_specialty ,business.industry ,Fulminant ,Hepatitis A ,Hepatitis B ,medicine.disease ,Chronic liver disease ,Chronic infection ,Hepatocellular carcinoma ,Pediatrics, Perinatology and Child Health ,medicine ,Intensive care medicine ,business ,Viral hepatitis - Abstract
Viruses are a common cause of hepatitis in children. Hepatitis A and E cause acute infections while Hepatitis B, C and D can lead to chronic infection with increased morbidity and mortality due to chronic liver disease and hepatocellular carcinoma in later life. Acute infections may be fulminant causing acute liver failure necessitating a liver transplant. Our understanding of these viruses continues to evolve, and this review aims to summarize the current strategies in diagnosis, prevention and use of anti-viral drugs to treat these infections.
- Published
- 2021
39. Pediatric Nonalcoholic Fatty Liver Disease
- Author
-
Paula Mrowczynski-Hernandez, Tania Mitsinikos, and Rohit Kohli
- Subjects
Male ,Pediatrics ,medicine.medical_specialty ,Adolescent ,medicine.medical_treatment ,Disease ,Liver transplantation ,Chronic liver disease ,Young Adult ,Non-alcoholic Fatty Liver Disease ,Risk Factors ,Nonalcoholic fatty liver disease ,medicine ,Humans ,Vitamin E ,Obesity ,Young adult ,Medical prescription ,Child ,Exercise ,Ultrasonography ,business.industry ,Fatty liver ,Alanine Transaminase ,medicine.disease ,Liver Transplantation ,Liver ,Child, Preschool ,Pediatrics, Perinatology and Child Health ,Elasticity Imaging Techniques ,Female ,business ,Diet Therapy - Abstract
Obesity has led fatty liver disease to become the most common chronic liver disease in children worldwide. Pediatric professional organizations have agreed that screening for fatty liver disease in children is the need of the hour. Once identified, prevention is key through appropriate dietary and activity prescriptions. Research continues to identify key pathways and genetic risk factors that predispose certain children to the more severe manifestations of this silent epidemic. We hope these novel observations lead to breakthrough treatments for these children that are severely impacted, such that they may no longer need liver transplantation as young adults.
- Published
- 2021
40. Epidemiology, risk factors, social determinants of health, and current management for non-alcoholic fatty liver disease in sub-Saharan Africa
- Author
-
O S Ojo, C Wendy Spearman, Chris Kassianides, Ponsiano Ocama, Omolade Betiku, Christian Tzeuton, Bilal Bobat, Mary Afihene, Hailemichael Desalegn Mekonnen, Leolin Katsidzira, Imran Paruk, Mark W. Sonderup, and Lina Cunha
- Subjects
Adult ,Male ,medicine.medical_specialty ,Social Determinants of Health ,Population ,Disease ,Chronic liver disease ,Cost of Illness ,Non-alcoholic Fatty Liver Disease ,Risk Factors ,Environmental health ,Epidemiology ,Prevalence ,Humans ,Medicine ,Obesity ,Social determinants of health ,Renal Insufficiency, Chronic ,Noncommunicable Diseases ,education ,Africa South of the Sahara ,Dyslipidemias ,Metabolic Syndrome ,education.field_of_study ,Hepatology ,business.industry ,Incidence ,Fatty liver ,Gastroenterology ,Disease Management ,Health Care Costs ,Awareness ,Middle Aged ,Prognosis ,medicine.disease ,Gastrointestinal Microbiome ,Diabetes Mellitus, Type 2 ,Hypertension ,Female ,Metabolic syndrome ,business ,Polycystic Ovary Syndrome - Abstract
Non-alcoholic fatty liver disease (NAFLD) is the leading cause of chronic liver disease globally and is estimated to affect approximately 25% of the world's population. Data about the prevalence and incidence of NAFLD in Africa are scarce, but the prevalence is estimated to be 13·5% for the general population. This is likely to be an underestimate considering the increasing burden of non-communicable diseases, particularly the rising prevalence of obesity and type 2 diabetes, driven by the overlapping challenges of food insecurity, nutritional transition, and associated increased consumption of calorie-dense foods. Establishing the true prevalence of NAFLD, raising public awareness around the risk factors behind the increase in NAFLD, and proactively addressing all components of metabolic syndrome will be important to combat this silent epidemic, which will have long-term health-care costs and economic consequences for the region.
- Published
- 2021
41. Clinical Features and Predictors for Mortality in Neurolisteriosis: An Administrative Data-Based Study
- Author
-
Rafael Garcia-Carretero
- Subjects
Pediatrics ,medicine.medical_specialty ,education.field_of_study ,business.industry ,Incidence (epidemiology) ,Listeria monocytogenes ,neurolisteriosis ,meningitis ,mortality ,risk factors ,Population ,Outbreak ,Disease ,medicine.disease ,Malignancy ,Chronic liver disease ,medicine ,education ,business ,Meningitis ,Kidney disease - Abstract
Listeriosis is an uncommon and potentially severe zoonotic bacterial infection that usually occurs in outbreaks instead of isolated cases. In recent years, there has been an increase in the incidence of this disease. One of the most severe of its complications involves the central nervous system (CNS) in a condition known as neurolisteriosis. Here, we describe the demographic and clinical features of patients presenting with neurolisteriosis between 2001 and 2015 using administrative data and attempt to identify potential predictors for mortality. We used the Spanish Minimum Basic Data Set at Hospitalization, a compulsory registry that collects data from clinical discharge reports. Up to 2015, data were coded based on the International Classification of Diseases, 9th Revision, so we used diagnoses and clinical conditions based on these codes. Age, sex, clinical presentation, mortality, and involvement of the CNS were identified. Using algorithms to aggregate data, variables such as immunosuppression and malignant disease were obtained. We analyzed correlations among clinical features and identified risk factors for morbidity and mortality. Between 2001 and 2015 we identified 5180 individuals, with a hospitalization rate of 0.76 per 100,000 population. Most (94%) were adults, and only 5.4% were pregnant women. The average age was 66 years. Neurological involvement was present in 2313 patients (44.7%), mostly meningitis (90.4%). Global mortality was 17%, but mortality in CNS infections was 19.2%. Age, severe sepsis, chronic liver disease, chronic kidney disease, and malignancy were the main risk factors for mortality in patients with CNS infections by Listeria monocytogenes. Although it is uncommon, neurolisteriosis can be a severe condition, associated with a high rate of mortality. Health care providers should be aware of potential sources of infection so that appropriate measures can be taken to prevent it.
- Published
- 2021
42. Dissecting the single-cell transcriptome underlying chronic liver injury
- Author
-
Jingni Wu, Bo Shen, Weiming Dai, Wei Hu, Junjun Wang, Xiaobo Cai, Teng Liu, Shengli Li, Lungen Lu, Zhenyang Shen, and Xiaoman Li
- Subjects
Liver injury ,Cell type ,Cell ,RNA ,RM1-950 ,macrophage ,single-cell transcriptome ,Biology ,medicine.disease ,Chronic liver disease ,cell-cell communications ,medicine.anatomical_structure ,ETS1 ,Drug Discovery ,Cancer research ,medicine ,chronic liver injury ,Molecular Medicine ,Original Article ,Therapeutics. Pharmacology ,Gene ,Chronic liver injury - Abstract
Chronic liver disease (CLD) is currently a major health problem worldwide, which is accompanied by chronic liver injury and lack of clinically effective treatment; however, systematic characterization of chronic liver injury procedures at single-cell resolution is lacking. In the present study, we established chronic liver injury mouse models and conducted single-cell RNA sequencing (scRNA-seq), including choline-deficient, ethionine-supplemented (CDE) and 3,5-diethoxycarbonyl 1,4-dihydrocollidinen (DDC) mouse models. We captured in total 16,389 high-quality cells and identified 12 main cell types in scRNA-seq data. Macrophages and endothelial cells are the largest cell populations in our dataset. Transcriptional trajectory analysis revealed different expression patterns of cells between CDE and DDC models and identified potential liver injury markers, such as Ets1, Gda, Itgam, and Sparc. Differential analysis identified 25 and 152 differentially expressed genes in CDE and DDC macrophages, respectively. In addition, 413 genes were detected to exclusively express in specific pseudotime states of macrophages. These genes were found to participate in immune-related biological processes. Further cell-cell communication analysis found extensive receding of cell-cell interactions between different cell types in the liver injury process, especially in the DDC model. Our study characterized the single-cell transcriptional landscape in the process of chronic liver injury, promoting the understanding of the underlying molecular mechanisms and providing candidate clinical strategy for effective intervention of chronic liver diseases., Graphical abstract, We systematically characterized single-cell transcriptome in two different liver injury mouse models by single-cell RNA sequencing (scRNA-seq).
- Published
- 2021
43. Non-alcoholic steatohepatitis and risk of hepatocellular carcinoma
- Author
-
Rafael S. Rios, Kenneth I. Zheng, Ming-Hua Zheng, and Yuan-Yuan Ji
- Subjects
Liver Cirrhosis ,medicine.medical_specialty ,Cirrhosis ,Carcinoma, Hepatocellular ,Hepatocellular carcinoma ,Disease ,Review Article ,Chronic liver disease ,Non-alcoholic Fatty Liver Disease ,Diabetes mellitus ,medicine ,Humans ,Obesity ,Intensive care medicine ,Non-alcoholic steatohepatitis ,business.industry ,Fatty liver ,Liver Neoplasms ,Insulin resistance ,General Medicine ,medicine.disease ,digestive system diseases ,Oxidative stress ,Metabolic associated fatty liver disease ,Medicine ,Steatohepatitis ,business ,Liver disease ,Progressive disease - Abstract
The emergence of non-alcoholic fatty liver disease (NAFLD) as the leading chronic liver disease worldwide raises some concerns. In particular, NAFLD is closely tied to sedentary lifestyle habits and associated with other metabolic diseases, such as obesity and diabetes. At the end of the disease spectrum, non-alcoholic steatohepatitis (NASH) may progress to cirrhosis and hepatocellular carcinoma (HCC), representing a serious health problem to modern society. Recently, an increasing number of HCC cases originating from this progressive disease spectrum have been identified, with different levels of severity and complications. Updating the current guidelines by placing a bigger focus on this emerging cause and highlighting some of its unique features is necessary. Since, the drivers of the disease are complex and multifactorial, in order to improve future outcomes, having a better understanding of NASH progression into HCC may be helpful. The risks that can promote disease progression and currently available management strategies employed to monitor and treat NASH-related HCC make up the bulk of this review.
- Published
- 2021
44. Steatosis, inflammasome upregulation, and fibrosis are attenuated in miR-155 deficient mice in a high fat-cholesterol-sugar diet-induced model of NASH
- Author
-
Yuan Zhuang, Shashi Bala, Michal Ganz, Gyongyi Szabo, Charles D. Calenda, Timea Csak, and Mrigya Babuta
- Subjects
Male ,medicine.medical_specialty ,Dietary Sugars ,Inflammasomes ,Diet, High-Fat ,Chronic liver disease ,Article ,Pathology and Forensic Medicine ,chemistry.chemical_compound ,Non-alcoholic Fatty Liver Disease ,Fibrosis ,Internal medicine ,NLR Family, Pyrin Domain-Containing 3 Protein ,Nonalcoholic fatty liver disease ,medicine ,Animals ,Molecular Biology ,Mice, Knockout ,Liver injury ,Triglyceride ,business.industry ,Inflammasome ,Cell Biology ,Lipid Metabolism ,medicine.disease ,MicroRNAs ,Endocrinology ,Gene Expression Regulation ,Liver ,chemistry ,Steatohepatitis ,Steatosis ,business ,medicine.drug - Abstract
Nonalcoholic fatty liver disease (NAFLD) is the most common cause of chronic liver disease globally. miRNAs (miRs) regulate various cellular events that lead to NAFLD. In this study we tested the hypothesis that miR-155 is an important regulator of steatohepatitis and fibrosis pathways. Wild type (WT) or miR-155 deficient (KO) mice received a high fat-high cholesterol-high sugar-diet (HF-HC-HS) for 34 weeks and liver tissues were analyzed. In patients with nonalcoholic steatohepatitis and in the mouse model of HF-HC-HS diet we found increased miR-155 levels in the liver compared to normal livers. Upon HF-HC-HS diet feeding, miR-155 KO mice displayed less liver injury, decreased steatosis, and attenuation in fibrosis compared to WT mice. ALT, triglyceride levels, and genes involved in fatty acid metabolic pathway were increased in WT mice whereas miR-155 KO mice showed attenuation in these parameters. HF-HC-HS diet-induced significant increase in the expression of NLRP3 inflammasome components in the livers of WT mice compared to chow fed diet. Compared to WT mice, miR-155 KO showed attenuated induction in the NLRP3, ASC, and caspase1 inflammasome expression on HF-HC-HS diet. Fibrosis markers such as collagen content and deposition, αSMA, Zeb2, and vimentin were all increased in WT mice and miR-155 KO mice showed attenuated fibrosis marker expression. Overall, our findings highlight a role for miR-155 in HF-HC-HS diet-induced steatosis and liver fibrosis.
- Published
- 2021
45. Analysis of antibody responses after COVID-19 vaccination in liver transplant recipients and those with chronic liver diseases
- Author
-
Mahak Chauhan, Paul J. Thuluvath, and Polly Robarts
- Subjects
Male ,medicine.medical_specialty ,COVID-19 Vaccines ,Cirrhosis ,Short Communication ,medicine.medical_treatment ,Liver transplantation ,Antibodies, Viral ,Chronic liver disease ,Gastroenterology ,Immunocompromised Host ,Internal medicine ,Outcome Assessment, Health Care ,medicine ,Humans ,Prospective Studies ,Adverse effect ,Liver transplant ,Immunocompromised ,Hepatology ,SARS-CoV-2 ,business.industry ,Liver Diseases ,Antibody titer ,COVID-19 ,Immunosuppression ,Middle Aged ,medicine.disease ,United States ,Liver Transplantation ,Vaccination ,Titer ,mRNA vaccine ,Antibody Formation ,Chronic Disease ,Spike Glycoprotein, Coronavirus ,Female ,business ,Immunosuppressive Agents - Abstract
Background &Aims Liver transplant (LT) recipients or other immunocompromised patients were not included in the registration trials of vaccine studies against SARS-CoV-2. Although clinical efficacy of COVID vaccines in immunocompromised patients was unknown, many societies had recommended vaccination of this highly vulnerable patient population. Methods In this prospective study, we determined antibody (Ab) response to spike protein, 4 weeks after the 2nd dose of mRNA vaccines or after the single dose of Johnson & Johnson vaccine, in LT recipients and those with chronic liver diseases (CLD) with and without cirrhosis. Results Of the 233 patients enrolled so far, 62 had LT, 79 had cirrhosis (10 decompensated) and 92 had CLD without cirrhosis. Ab titers were defined as undetectable (250 U/mL). Of the 62 patients who had LT, Ab levels were undetectable in 11 patients and suboptimal (median titer 17.6, range 0.47 - 212 U/mL) in 27 patients. Among 79 patients with cirrhosis, 3 had undetectable Ab and 15 had suboptimal (median titer 41.3, range 0.49 - 221 U/L) response. Of the 92 patients without cirrhosis, four had undetectable Ab and 19 had suboptimal (median titer 95.5, range 4.9 - 234 U/L) Ab response. Liver transplantation, use of 2 or more immunosuppression medications and vaccination with a single dose of Johnson & Johnson vaccine were associated with poor immune response on multivariable analysis. No patient had any serious adverse events. Conclusions Poor antibody response after SARS-CoV-2 vaccination was seen in 61% of LT recipients and 24% of those with CLD. Lay summary The clinical efficacy of COVID vaccines in immunocompromised patients is unknown. We did a prospective study to evaluate immune responses to COVID vaccines (Moderna, Pfizer or Johnson & Johnson) in 62 liver transplant recipients, 79 subjects with cirrhosis and 92 subjects with chronic liver diseases without cirrhosis. We found that 17.8% of liver transplant recipients, 3.8% of those with cirrhosis and 4.3% of those with chronic liver diseases without cirrhosis had undetectable antibody levels. In total, 61.3% of liver transplant recipients and 24% of those with chronic liver diseases (with or without cirrhosis) had poor antibody response (undetectable or suboptimal). Liver transplantation, use of immunosuppressive medications and vaccination with a single dose of Johnson & Johnson vaccine were associated with poor antibody response when adjusted for other factors., Graphical abstract
- Published
- 2021
46. Paediatric acute liver failure: a practical approach
- Author
-
Harveen Singh and Girish Gupte
- Subjects
Prothrombin time ,Pediatrics ,medicine.medical_specialty ,medicine.diagnostic_test ,business.industry ,Liver failure ,Vitamin k ,medicine.disease ,Chronic liver disease ,Supportive psychotherapy ,Pediatrics, Perinatology and Child Health ,Coagulopathy ,Medicine ,business ,Hepatic encephalopathy ,Paediatric patients - Abstract
Acute liver failure (ALF) in the paediatric patient is a multisystem complex disorder, which occurs in the absence of chronic liver disease. Globally, viruses remain a common cause but drugs, metabolic and autoimmune conditions are important triggers. In up to half of cases no specific cause is identified. The definition entails a coagulopathy with a Prothrombin time (PT) ≥ 15seconds or International Normalized Ratio (INR) ≥ 1.5 not corrected by vitamin K in the presence of hepatic encephalopathy (HE) or a PT ≥ 20 or INR ≥2 or above regardless of HE. HE can be difficult to recognize in children and is defined differently than HE in adults. Timely recognition of ALF improves outcomes and allows time to undertake investigations, provide supportive therapy and arrange transfer to a specialist paediatric liver centre with transplant capacity. The purpose of this article is to review the aetiologies of ALF in children and outline an approach to investigation, management and treatment.
- Published
- 2021
47. Hepatopulmonary syndrome: An update
- Author
-
Munish Sharma, Salim Surani, Kejal D Gandhi, and Pahnwat Taweesedt
- Subjects
Pediatrics ,medicine.medical_specialty ,integumentary system ,Hepatology ,business.industry ,Hepatopulmonary syndrome ,Chronic liver disease ,Intrapulmonary vasodilatation ,Liver failure ,Minireviews ,respiratory system ,medicine.disease ,eye diseases ,Hypoxemia ,hemic and lymphatic diseases ,medicine ,business - Abstract
Hepatopulmonary syndrome (HPS) is characterized by defects in oxygenation caused by intra-pulmonary vasodilation occurring because of chronic liver disease, portal hypertension, or congenital portosystemic shunts. Clinical implications of portal hypertension are very well-known, however, awareness of its effect on multiple organs such as the lungs are less known. The presence of HPS in chronic liver disease is associated with increased mortality. Medical therapies available for HPS have not been proven effective and definitive treatment for HPS is mainly liver transplantation (LT). LT improves mortality for patients with HPS drastically. This article provides a review on the definition, clinical presentation, diagnosis, and management of HPS.
- Published
- 2021
48. Influence of Probiotics Administration Before Liver Resection in Patients with Liver Disease: A Randomized Controlled Trial
- Author
-
Tortajada Pauline, Brasse-Lagnel Carole, Tuech Jean-Jacques, Roussel Edouard, Bekri Soumeya, Papet Eloise, Montialoux Helène, and Schwarz Lilian
- Subjects
medicine.medical_specialty ,Carcinoma, Hepatocellular ,Cirrhosis ,business.industry ,Probiotics ,medicine.medical_treatment ,Liver Neoplasms ,medicine.disease ,Chronic liver disease ,Gastroenterology ,Liver disease ,Resectable Hepatocellular Carcinoma ,Internal medicine ,Hepatocellular carcinoma ,medicine ,Clinical endpoint ,Hepatectomy ,Humans ,Surgery ,Liver function ,business - Abstract
By inhibiting the growth of pathogenic bacteria and modulating the local intestinal immune system, probiotics may reduce bacterial translocation and systemic endotoxaemia, factors partially responsible for post-operative complications following liver resection for hepatocellular carcinoma in patients with cirrhosis. Patients with resectable hepatocellular carcinoma developed in the setting of chronic liver disease were prospectively divided into two equal-sized groups: one receiving probiotic treatment 14 days prior to surgery and the other receiving placebo. The primary endpoint was the level of circulating endotoxins after hepatectomy. Secondary endpoints were systemic inflammation (inflammatory cytokine levels), post-operative liver function and overall post-operative complication rate. From May 2013 to December 2018, 64 patients were randomized, and 54 patients were included in the analysis, 27 in each arm. No significant change in endotoxin levels was observed over time in either group (P = 0.299). No difference between the groups in terms of post-operative liver function and overall complication rates was observed. The only differences observed were significant increases in the levels of TNFalpha (P = 0.019) and interleukin 1-b (P = 0.028) in the probiotic group in the post-operative period. Contrary to the modest data reported in the literature, the administration of probiotics before minor liver resection for hepatocellular carcinoma developed in the setting of compensated chronic liver disease does not seem to have an impact on circulating endotoxin levels or post-operative complication rates. Trial registration: NCT02021253.
- Published
- 2021
49. Liver pathology in pregnancy
- Author
-
Kiyoko Oshima and Jacqueline E Birkness-Gartman
- Subjects
Pathology ,medicine.medical_specialty ,Cholestasis, Intrahepatic ,Chronic liver disease ,Pathology and Forensic Medicine ,Acute fatty liver of pregnancy ,Bile Acids and Salts ,Liver disease ,Fetus ,Pre-Eclampsia ,Cholestasis ,Pregnancy ,Hyperemesis Gravidarum ,Humans ,Medicine ,Eclampsia ,business.industry ,Liver Diseases ,Focal nodular hyperplasia ,Hypertension, Pregnancy-Induced ,General Medicine ,medicine.disease ,Fatty Liver ,Pregnancy Complications ,Liver ,Female ,business ,Cholestasis of pregnancy - Abstract
Liver dysfunction occurs in up to 3% of pregnancies and can be due to pregnancy-associated liver injury, exacerbation of pre-existing liver disease, or co-incident with pregnancy. The most common form of pregnancy-associated liver injury is intrahepatic cholestasis of pregnancy (ICP). This condition is typically benign and self-limited, but is associated with fetal morbidity and mortality with high levels of serum bile acids. Acute fatty liver of pregnancy (AFLP) and the hypertensive disorders of pregnancy (including pre-eclampsia, eclampsia, and hemolysis, elevated liver enzymes, and low platelets [HELLP] syndrome) are more commonly associated with maternal and fetal complications and may necessitate expedient delivery. Histologically, ICP shows nonspecific features of cholestasis, while AFLP and the hypertensive disorders have more characteristic histologic findings. While not a true liver disease, hyperemesis gravidarum can cause elevated liver enzymes. Pregnant patients are at increased risk of developing severe hepatitis E and herpesvirus infections, Budd-Chiari syndrome, and gallstones, and they may also experience worsening of known chronic liver disease. Mass lesions in pregnancy including hemangiomas, focal nodular hyperplasia, and hepatocellular adenomas and carcinomas can present unique challenges for diagnosis and management. This review will explore the pathophysiology, presentation, histologic features, and management of these conditions.
- Published
- 2021
50. Development and multicenter validation of FIB‐6: A novel, machine learning, simple bedside score to rule out liver cirrhosis and compensated advanced chronic liver disease in patients with chronic hepatitis C
- Author
-
Mai S. Mabrouk, Reham Soliman, George N. Dalekos, Moutaz Derbala, Necati Örmeci, Khalid Alswat, Ayman A. Abdo, Nabiel Mikhail, Gamal Shiha, Waseem Hamoudi, Faisal M. Sanai, Said A. Al-Busafi, Fathiya El-Raey, Samir Y. Marzouk, Ala I. Sharara, Samy Zaky, and Hidenori Toyoda
- Subjects
Cirrhosis ,Hepatology ,medicine.diagnostic_test ,Receiver operating characteristic ,business.industry ,Hepatitis C ,medicine.disease ,Chronic liver disease ,Machine learning ,computer.software_genre ,Liver disease ,Infectious Diseases ,Fibrosis ,Liver biopsy ,medicine ,Artificial intelligence ,Stage (cooking) ,business ,computer - Abstract
BACKGROUND Non-invasive tests (NITs), such as Fibrosis-4 index (FIB-4) and the aspartate aminotransferase-to-platelet ratio index (APRI), developed using classical statistical methods, are increasingly used for determining liver fibrosis stages and recommended in treatment guidelines replacing the liver biopsy. Application of conventional cutoffs of FIB-4 and APRI resulted in high rates of misclassification of fibrosis stages. AIM There is an unmet need for more accurate NITs that can overcome the limitations of FIB-4 and APRI. PATIENTS AND METHODS Machine learning with the random forest algorithm was used to develop a non-invasive index using retrospective data of 7238 patients with biopsy-proven chronic hepatitis C from two centers in Egypt; derivation dataset (n = 1821) and validation set in the second center (n = 5417). Receiver operator curve analysis was used to define cutoffs for different stages of fibrosis. Performance of the new score was externally validated in cohorts from two other sites in Egypt (n = 560) and seven different countries (n = 1317). Fibrosis stages were determined using the METAVIR score. Results were also compared with three established tools (FIB-4, APRI, and the aspartate aminotransferase-to-alanine aminotransferase ratio [AAR]). RESULTS Age in addition to readily available laboratory parameters such as aspartate, and alanine aminotransferases, alkaline phosphatase, albumin (g/dl), and platelet count (/cm3 ) correlated with the biopsy-derived stage of liver fibrosis in the derivation cohort and were used to construct the model for predicting the fibrosis stage by applying the random forest algorithm, resulting in an FIB-6 index, which can be calculated easily at http://fib6.elriah.info. Application of the cutoff values derived from the derivation group on the validation groups yielded very good performance in ruling out cirrhosis (negative predictive value [NPV] = 97.7%), compensated advance liver disease (NPV = 90.2%), and significant fibrosis (NPV = 65.7%). In the external validation groups from different countries, FIB-6 demonstrated higher sensitivity and NPV than FIB-4, APRI, and AAR. CONCLUSION FIB-6 score is a non-invasive, simple, and accurate test for ruling out liver cirrhosis and compensated advance liver disease in patients with chronic hepatitis C and performs better than APRI, FIB-4, and AAR.
- Published
- 2021
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.